A Celebration Of The Oldest Person On Record: Calment’s Day

A Celebration Of The Oldest Person On Record: Calment’s Day

On the 21st of February this year there will be a celebration of the birthday of 122-year old Jeanne Calment, the oldest verified human being ever  [1875 – 1997]. This is an initiative launched by longevity advocate Victor Björk, and the celebration involves posting a picture of oneself consuming Calment’s favourite foods (olive oil/dark chocolate/port wine)

So who was Jeanne Calment?

Calment lived alone without any help at all until aged 110, when she moved into a nursing home, not because she needed to, but because of a fire in her apartment. Aged 114 she was still able to take care of herself and walk up and down stairs without help. However, shortly before her 115th birthday she fell down a stairway and never fully recovered her ability to walk. When Calment was 118 years old she went through several thorough cognitive tests, and surprisingly she scored within the normal range of a person without dementia, despite by now being physically frail and requiring a wheelchair.

Since aging itself is the major cause of death, extreme ages are only reached by people aging biologically slower. Calment is therefore so far the slowest-aging individual ever recorded. It is also clear from looking at pictures of her that she looked better than expected at different ages, so all that we know is that “something” (a rare genetic combination paired with epigenetic expression) slowed her aging process. But what was that “something”? We will likely not find out, as an autopsy was not done and genome sequencing did not exist back then.

Personally, I think the historical lack of research on maximum lifespan is a problem, reducing focus on what stops us from getting even older. While lots of biomedical research is chasing low-hanging fruit like diabetes, as of 2016 precious little is being done to study the pathologies of the oldest old, which sharply limit human lifespan (Read more on this in a previous article)

The new Calment’s of the future?

Dmitry Kaminskiy, Moldovan businessman and director of Deep Knowledge Ventures (a company focusing on investment in upcoming anti-aging biotechnologies) offers a $ 1 million dollar price for the first person to reach 123 (201 days older than Calment at age of death). This might superficially seem like an easy record since longevity is increasing globally, however 98% of people living to 110 fail to reach 115 and no one else has reached within 3 years of Calment’s age at death. Nevertheless it remains an interesting question who the first 123-year old is going to be, and one should expect someone to reach it within at least a few decades. However will that 123-year old have achieved this “naturally”, or will it be a centenarian who has been treated with some partially “rejuvenating” medical treatments?.

So on the 21st of February we will commemorate Calment by consuming her favourite foods, olive oil/dark chocolate/wine. Post your picture and check out the facebook event here

Future Day – March 1, 2013 – theme “longevity”

Since 2012, there has been a global initiative to institute March 1 as an international “Future Day” dedicated to envisioning and working for a better future. In 2013, it was proposed to make “Longevity” the special theme of that day in that year, and mark this theme by conducting meetings and study groups in different countries, dedicated to discussions of longevity, on that day. That first of its kind international action in support of longevity research was a success. People from over 20 countries organized events, ranging from meetings with a few like-minded friends to mini-conferences and seminars, through lobbying actions to online communications. This was just a first drill and further actions of this kind will take place in the future.  Such events can be a very positive and unifying force both for the local and international life-extensionist communities and organizations, and ultimately for the social acceptance of our cause. Notably, the celebrations of the Future Day were not (and could not) be restricted just to the topic of longevity, and many organizations were involved and organized events, including International Longevity Alliance (ILA), Humanity+, Heales, LongeCity, various national transhumanist and life-extensionist associations, such as British Longevity Society, the Russian Transhumanist Movement, the Brazilian Transhumanist Association, the Mormon Transhumanist Association, and many more – with members often belonging to several allied organizations at one at the same time. Below I list all the events celebrated on that day that I am aware of, regardless of their “official” affiliation and emphasis. Yet, essentially, in all of these events, people expressed an optimistic and proactive attitude toward the future, in which the promotion of longevity is an indispensable component, moreover the promotion of longevity almost automatically brings in its train the advancement of other positive life-preserving and life-enhancing tasks: peace, science, education, quality of life, equality. It is to be hoped that all our joint efforts will contribute even minimally to their achievement.

Ilia Stambler – event coordinator.

And here are the reports from around the world (as were made back in 2013):

1. Russia. Maria Konovalenko and Daria Khaltourina report: We celebrated Future Day yesterday. Actually, even twice) Alexey Turchin, Peter Fedichev and Mikhail Batin discussed the possible future scenarios of our civilization at Expert Online round table. Life extension and its social implications were the main topics of this stimulation conversation. Later in the evening the Russian Transhumanist Movement celebrated Future Day under the sign of radical life increase. Valeria Pride, Danila Medvedev, Maria Konovalenko, Daria Khaltourina, Viktor Zykov, Elena Milova, Igor Kirilyuk, and others gathered together to celebrate and to share their plans in fighting aging for the following year.

 

 

In the picture, celebrations by the Russian Transhumanist Movement (left to right): Maria Konovalenko, Viktor Zykov, Igor Kirilyuk, Daria Khaltourina.

 

In the picture: Round Table at Expert TV, including: Alexey Turchin, Maria Konovalenko, Peter Fedichev, Mikhail Batin

2. Ukraine Elen Obabkova, Andrey Vergazov and Anton Kulaga report: An open conference was organized on the Future Day in Smart Cafe Bibliotech in Kiev, by Ukrainian Transhumanists. The program included presentations by Alexander Koliada “On the way to personalized medicine,” Vania Pasechnik “Hacker space – the community of the future” Evgeny Sluzko “Venus project – future without politics, poverty and war”, Anton Rzhevsky “Ecology and technology: How do we influence the Future”.

 

 

In the picture, the future day organizers and presenters: Elen Obabkova, Anton Kulaga, Evgeny Sluzko,  Andrey Vergazov, Alexander Koliada, Anton Rzhevsky, Vania Pasechnik

 

In the picture: the attendees of the Kiev Celebration of the Future Day.

3. Venezuela: Greetings and mutual support were kindly and generously shared among different countries during this day. Thus the Ukrainian event was greeted by Jose Cordeiro – President of the Venezuela branch of the “Millenium Project”, professor at the Singularity University, and an active promoter of radical life extension in South America and around the world. Here’s the video greeting. On March 1, Jose was preparing a documentary about Radical Life Extension for the History Channel.

4. Republic of Georgia, Jaba Tkemaladze reports: On March 1, students and professors of the International Black Sea University interested in Transhumanism, as well as students of Grigol Robakidze University, Tbilisi, gathered at the conference hall of Grigol Robakidze University to celebrate Future Day. Ministers of health and of education were invited, but did not attend. The newspaper “Asaval – Dasavali” interviewed the organizer, Dr. Jaba Tkemaladze. After the meeting at Grigol Robakidze University, an additional meeting took place at the Club of Young Scientists with the representative of Shota Iamanidze Foundation – Irina Iamanidze, and editor of the cultural-philosophical journal “Homli” Nino Sadgobelashvili. There was reached an agreement to cooperate. Technical details of the cooperation were considered. There emerged the idea to create an educational internet portal for those who wish to live in the future-oriented civilization, and are even now ready to change their habits of life.

 

In the picture: Dr. Jaba Tkemaladze conducts a Seminar on the Future Day at Grigol Robakidze University, Georgia.

5. UK. Dr. Marios Kyriazis reports: The activities in the UK went very well. We concentrated mostly on targeted political information, specifically: – We contacted members of the UK Parliament with information about longevity, life extension and the need for dialogue and funding. – We discussed issues of longevity and politics at a meeting with senior members of age-related organisations in the UK, and planned a way forward. For example, we planned a major meeting at the House of Lords in 29th October 2013. For the 1st October we will be organising meetings in Cyprus as we will be there for some weeks.

6. Israel. Ilia Stambler (myself) reports: On March 1, Future Day dedicated to the pursuit of longevity, a seminar was held in Bar Ilan University. The program included a lecture on the “Past and present of life extension”, a report about activities of the “International Longevity Alliance”, and then a brainstorming session on the ways Israeli pro-longevity activists can make a practical impact. Several long time veterans in the fight for healthy longevity were present: Dr. Yaakov Ben-Shaul, Dr. Rafael Marilus, Dr. Amit Fliess, Dr. Tal Galili, Dr. Eli Eshed, as well as participants from all walks of life – students, soldiers, workers. Some of the potential actions may include cooperation in collecting and processing data related to aging, social promotion of preventive medicine, and creating study groups.

 

In the picture: Bar Ilan University, Israel, the venue of the Future Day seminar. In the heat of discussion, i forgot to take pictures of the meeting. So here is a picture of Bar Ilan university, that people believe i was there (not perfect). The picture goes to all those who did not take or did not send pictures…

7. France. Edouard Debonneuil reports

I held a meeting in Café el Sur in Paris. It was a nice first try, there were good friends of mine as well as people I had not met yet. The discussion was great and covered a wide range of topics, with a particular focus on associations (ILA, Heales, Longévité & Santé, Sceaux Longévité Santé, Association Française Technoprogressiste), projects (Quantified Health and incitative pedometers, Linking Researchers, next conferences in France, an ongoing thesis), PR (longevity & health, aging as the root of most diseases today), organizational structures (fonds de dotation lié à une association reconnue d’intérêt général), health data collection and law (CNIL, données minimales requises et possibilité de travailler avec des des données non personnalisées), promises of ongoing research (in worms, in mice, NBIC) and how society gradually integrates longevity increases.

 

 

In the picture: Dinner on Future Day at Café el Sur. Paris. (Edouard – second from right)

8. Japan. John Leonard reports: The Longevity Alliance Japan had our first meeting on March 1st (Future Day) 2013 in Akihabara, Tokyo. Our group was small but I think it was a very big step! Meeting with each other in person created inspiration and motivation to really pursue longevity causes. And Miriam Ji Sun (Miriam Leis) adds: Mainly we discussed our interest in future-oriented topics (incl. robotics, biostasis research, biotech, regenerative medicine and longevity research) and how we came to got to know about them. It turned out that we all have similar networks in common. Some next steps would focus on growing our network in Japan.

 

In the picture (left to right): Miriam Ji Sun, Erico Narita, John Leonard

9. USA. Utah. Lincoln Cannon reports: The Mormon Transhumanist Association sponsored a Future Day lunch at Thanksgiving Point in Utah. All enjoyed casual conversation on such subjects as news of brain-to-brain interfacing between mice, comparisons of libertarian socialism and benevolent authoritarianism, and release of a new edition of Mormon scriptures by the LDS Church. A particularly passionate debate arose around the topic of maintaining identity during radical longevity or shared consciousness. We look forward to continuing these and related conversations at the 2013 Conference of the Mormon Transhumanist Association on 5 April in Salt Lake City. In the US, further meetings on Future Day (as far as I am aware) took place at Stanford University, California, and San Jose, California.

10. Portugal. Vanderlei Martinianos reports: A meeting was held at Café A Brasileira in the heart of Lisbon, and after gathering everybody, the participants headed to have dinner at Fabulas Restaurant. At Fabulas the participants celebrated the day as well as discussed about “The Evolution: The Future”, a novel written by Marco Santini (Foreword by Vanderlei Martinianos)  that was freely distributed. Mind uploading and longevity were also discussed.

 

 

According to Vandelei Martinianos: This is a picture related to the Future Day’s celebration in Lisbon. Note that I have created the F sign made with hands to recall the word F as in FUTURE. So I asked everybody to do it in order to celebrate the day.

11. Brazil.    Vandelei Martinianos together with Leo H.M. Arruda, Isabel Alves and Gustavo Rosa Diego Caleiro and João Lourenço coordinated two meetings that were held on Future Day in Rio De Janeiro and São Paulo. A third meeting took place on that day in Brazil in Santa Maria (in the Southern part of the country): Mateus Stein reports about the meeting in Santa Maria: We had a great conversation about longevity, transhumanism, emerging technologies and our expectations about the future for almost three hours. It was worth it to have had this meeting because of our conversation and friendship, but I’m still disappointed because it would be better if more people could be with us.

12. Belgium. Didier Coeurnelle reports: A meeting was held in Brussels, on 1st of March, in the Café ‘A la mort subite’. We had an interesting conversation during two hours among other things about · The most important progresses that we expect/hope to see concerning longevity in the next decades · The biggest risks related to (opposition to) life extension technological progression that we are afraid to see in the next decades

13. Canada, Edmonton. According to Kim Solez: University of Alberta Campus featured music by Joel Crichton, two student presentations by Damon Monroe – Plight of Globalization of Technology, Vanessa Rogers – From Sense to Intelligence: Enhancement of the Human Mind.; Excerpts from Doug Wolens The Singularity documentary with some fun interruptions, Three more student presentations, by Matt Herman – The Future of Freedom and Security. Peter Wood – Echocardiography: The Future of Cardiac Imaging. Diane Laverty – Genomics: Letting the Gen(i)e out of the Bottle. More Joel Crichton music, dancing and merriment!

14. Australia. According to Adam Ford, Future Day was held in Melbourne as a joint project of Amplify, Second Tree, Humanity+ and Singularity Summit AU. The program included: Welcome by Adam Ford, Director Humanity+, and presentations by Peter Ellyard on “Rapid prototyping the Future” (extremely participatory), a presentation, by Mark Ciotola (formely at NASA) on“The Future of Space Exploration”, and by James Newton-Thomas (Engineer, Field Roboticist) on “Automation, and The Future of Work.”

15. China Special thanks to Adam Ford for providing this interview with Dr. Ben Goertzel (currently researching AI in Hong Kong, China) — the man who originated the idea of the Future Day. And now Ben joined in the celebration of Longevity on that day. Watch the video of Ben Goertzel on Longevity

16. India. According to Siddartha S. Verma

A meeting was held in Ranchi, Jharkhand, India. Attention and awareness to this day will let the younger generation to understand the hidden potential behind emerging technologies and rapid technological acceleration.

17. South Africa. According to Belinda Metlitsky Silbert

“Since 2012, there has been a global initiative to institute March 1 as an international “Future Day” dedicated to envisioning and working for a better future.” In honor of that day, Belinda Metlitzky Silbert  gave a free talk on Healthy Longevity at Marina Da Gama, SA. 18. Finland.  The future day was celebrated in Tampere, Finland, by Longevity Finland.

19. Romania. According to Mihai Cirimpei

A meeting in support of longevity was held in Bucharest at the CUGET research group. 

20. Korea. Dr. Kyung-Jin Min delivered a lecture on aging research at the retreat of Incheon Central Church.

 

In the picture: Prof. Kyung-Jin Min with a group of students at the spring camp of Incheon Central Church.

21. The Netherlands. On March 1, Amanda Stoel organized “Health and Longevity Day” for a narrow circle in Bussum, near Amsterdam.

22. Italy. David de Biasi reports (according to Massimiliano Maidano): We met at the Galleria Alberto Sordi (A gallery dedicated to a famous Italian Actor ) in Rome. We talked about cryonics, politics and technology for a couple of hours.

23. Germany. Daniel Wuttke organized the submission of two proposals for longevity research to develop the Denigma (Deciphering the Enigma of Aging) platform (http://www.denigma.de/): “Quantified Self Intelligent Collective Platform For More Healthy Life Years” as a Commitment to the Action Plan of the European Innovation Partnership on Active and Healthy Ageing (EIP AHA) and another entitled “Crowdsourcing for the Biological Sciences: Open Distributed Science for Ageing Research”.

In several more countries there were efforts to organize events dedicated to longevity on the Future Day: Egypt, Mexico, Poland, Denmark, Ireland, Uganda, Philippines.  Yet, it was still difficult to gather the initial support. This is not at all discouraging, for the mere fact that such efforts take place is the best hope for the international movement for healthy longevity for all.

Looking forward to more and even stronger initiatives of this kind!

Trường thọ

Trường thọ

Chúng tôi ủng hộ sự tiến bộ của tuổi thọ khỏe mạnh cho toàn bộ dân số thông qua nghiên cứu khoa học, y tế công cộng, vận động và hoạt động xã hội. Chúng tôi nhấn mạnh và thúc đẩy cuộc đấu tranh chống lại kẻ thù chính của tuổi thọ khỏe mạnh – quá trình lão hóa.
Quá trình lão hóa là gốc rễ của hầu hết các bệnh mãn tính đau đớn dân số thế giới. Quá trình này làm cho tỷ trọng lớn nhất của người khuyết tật và tử vong, và cần phải được điều trị phù hợp. Xã hội cần dành nỗ lực hướng tới điều trị và điều chỉnh của nó, như đối với bất cứ căn bệnh vật chất khác.
Các vấn đề của lão hóa là nghiêm trọng và đe dọa. Tuy nhiên, chúng ta thường chứng kiến sự lãng quên gần như hoàn toàn với thực tế và mức độ nghiêm trọng của nó. Có một xu hướng nhẹ nhàng để bỏ qua tương lai, để đánh lạc hướng tâm từ lão hóa và tử vong do lão hóa, và thậm chí để trình bày quá trình lão hóa và chết trong một ánh sáng gây hiểu nhầm, xin lỗi và không tưởng. Đồng thời, có một niềm tin vô căn cứ rằng lão hóa là một quá trình không thể lay chuyển hoàn toàn không thể quản lý. coi thường này của vấn đề và ý nghĩa vô căn cứ này bất lực không góp phần vào việc cải thiện sức khỏe của người già và tuổi thọ khỏe mạnh của họ. Có một nhu cầu để trình bày các vấn đề trong mức độ đầy đủ của nó và tầm quan trọng và hành động để giải quyết hoặc giảm thiểu nó đến hết khả năng của chúng tôi.
Chúng tôi kêu gọi nâng cao nhận thức của công chúng về các vấn đề lão hóa trong phạm vi đầy đủ của nó. Chúng tôi kêu gọi công chúng để nhận ra vấn đề nghiêm trọng này và dành những nỗ lực và nguồn lực – trong đó có nguồn lực kinh tế, xã hội, chính trị, khoa học, công nghệ và truyền thông – để giảm tối đa khả năng của mình vì lợi ích của dân số lão hóa, kéo dài tuổi thọ cho sức khỏe của họ. Chúng tôi thúc đẩy ý tưởng rằng sự trưởng thành về tinh thần và tâm linh và sự gia tăng tuổi thọ khỏe mạnh không đồng nghĩa với sự lão hóa và thoái hóa.
Chúng tôi ủng hộ việc tăng cường và đẩy mạnh nghiên cứu y sinh học cơ bản và ứng dụng, cũng như sự phát triển của công nghệ, công nghiệp, môi trường, y tế công cộng và các biện pháp giáo dục, đặc biệt là đạo diễn cho tuổi thọ khỏe mạnh. Nếu được hỗ trợ đầy đủ, các biện pháp như vậy có thể tăng tuổi khỏe mạnh tuổi thọ của dân số già, thời gian sản xuất của họ, đóng góp của họ cho sự phát triển của xã hội và nền kinh tế, cũng như ý thức của họ về hưởng thụ, mục đích và giá trị của cuộc sống.
Chúng tôi ủng hộ sự phát triển của các biện pháp khoa học để mở rộng cuộc sống khỏe mạnh được sự hỗ trợ công cộng và chính trị có thể tối đa mà nó xứng đáng, không chỉ bởi các cộng đồng nghề nghiệp mà còn bởi sự rộng rãi công chúng.

Gerontological Manifesto

The Gerontological Manifesto

By Alexey Olovnikov, PhD

The necessity to create various remedies for degenerative age-related diseases is beyond any doubts. But this process is somewhat like a Sisyphean task, because the aging of each person only deepens over time, persistently destroying the results of treatment. Pharma is forced to deal with the countless consequences, rather than with their cause. The primary cause of aging is still deeply buried in gerontological terra incognita. Meanwhile, a growing and imminent new threat for humankind is becoming increasingly apparent. This threat is the increasing aging of the human population as a whole. The menace to the society is in the ongoing change in the ratio of the able-bodied and the disabled-bodied populations in the advanced countries. This trend may lead to the numerical superiority of disabled old persons already by the middle of the 21st century. According to the current estimates, the medical expenses on non-communicable diseases for the period 2010-2030 will be $47 trillion by 2030, with two thirds of this sum to be linked to the costs of the elderly healthcare. (http://www.weforum.org/news/non-communicable-diseases-cost-47-trillion-2030-new-study-released-today) A solution to this problem by attracting young migrants only shifts the burden of care to the countries of exodus. If no action is taken to radically enhance the ongoing studies in the field of aging biology, this problem will became a burden unbearable for our civilization: Humanity will not be able to maintain the elderly people! The solution to such a gerodemographic situation, the potentially fatal and vitally important problem, can be achieved only through a radical slowing down of the pace of the aging process, or by stopping it! And this can be done only via the discovery of the primary causes of aging that still remain elusive. The search for medicines against degenerative diseases of aging and the studies of the primary mechanism(s) of aging are two related but clearly independent tasks. The striving to the radical slowing down of aging is as important today as the struggle against infectious pandemics was in the past. Even under the most favorable scenario, several decades will be spent until finding the conditions for the radical slowing down of mammalian aging (and for the subsequent translation of the results to the clinic). But within the next several decades, the number of disabled elderly people in the developed countries can exceed the number of able-bodied adults. The favorable resolution of this unprecedented historic challenge can be found only in case of the unprecedented concentration of intellectual and financial efforts in a new life extension project. The enemy, that has quietly crept up onto our civilization, is quite capable of either destroying the basic moral values (in the way of forced absence of care for the elderly), or undermining the financial foundations of the society (in the way of the back-breaking costs of servicing the elderly). A more likely scenario is that it will do both! The non-biological alternatives to the ongoing efforts in biology and medicine are the robots, but they are not ready to take the frail portion of mankind on their iron shoulders. But even with the robots, the humans would hardly have forgotten their oldest dream – the dream of a significant life extension. Non-aging or delayed aging in essence means the potential for a very long healthy life. A potential critic may argue that a very long healthspan will lead to overpopulation. However the answer to this objection is known. The experience of birth control on the large state scale has already been gained, albeit with other goals. It is of course possible to leave everything as it is, so that life itself will put everything in its place. Life will do it, but at the cost of mass misery and huge losses. Are those necessary or can be avoided by human effort?

And finally we should note one of the most formidable companions of aging – cancer. It is known that, after sexual maturity, cancer incidence increases exponentially with age (de Magalhães JP. How ageing processes influence cancer. Nat Rev Cancer. 2013 May;13(5):357-65.). Why? According to a widespread view, occasional changes in chromosomal DNA accumulate as long as there will appear some fatal mutations. However, there are some facts that do not fit into such a simple scheme, and therefore, a generally accepted theory of cancer origin is still absent. There are reasons to suppose that the genuine cause of this multiform pathology is the non-mutational flaws in the functioning of a special, so called chronographic, mechanism. This hypothetical mechanism directs the timely sequential changes of the body structures (hence, it directs the control over the biological age of an individual organism) in the course of the development, maturation and aging of multicellular organisms (Olovnikov A.M. Chronographic Theory of Development, Aging, and Origin of Cancer: Role of Chronomeres and Printomeres. Current Aging Science, 2015, Vol. 8, No.1, 76-88.). Non-mutational errors, which rarely occur during the functioning of this mechanism changing the age, can lead to a loss of proper genetic control in some cells. Only after that, the progeny of these cells begins to obtain and accumulate mutations which eventually can give rise to a malignant growth. If so, the delaying of aging can bring another nice bonus – the prevention of cancer. The sooner we will get this bonus, the better for all of us.

Alexey M. Olovnikov   

olovnikov@gmail.com

January 19, 2016

https://healthspanpolicy.org/person/alexey-matveyevich-olovnikov/

alexey-olovnikov2 Alexey Matveyevich Olovnikov, PhD, Institute of Biochemical Physics, Russian Academy of Sciences.

In 1971, Olovnikov was the first to recognize the problem of the DNA end underreplication and to suggest the telomere hypothesis of cellular aging and the relationship of telomeres to cancer. In more details: 1) He predicted telomere DNA shortening during normal cell doublings and foretold the correlation between telomere length and the cell doublings potential, or Hayflick’s limit; 2) He predicted also the existence of a compensatory DNA polymerase responsible for maintenance of telomeres (now the compensatory enzyme is known as telomerase); 3) He supposed that cancer cells should have the same compensatory DNA polymerase (telomerase) as the  germline cells, and assumed that this enzyme endows cancer cells, like the  germline cells, with their immortality; 4) In addition, Olovnikov interpreted a circular form of bacteria’s genome as a means of protection of their DNA from shortening.

History has shown the validity of these basic predictions and explanations that were made by Olovnikov at the tip of a pen and essentially began a new area of research. Later, other researchers, for their experimental demonstration of how chromosomes are protected by telomeres and the enzyme telomerase, were awarded the Nobel Prize (2009).

Currently, A.M. Olovnikov is elaborating a new “Chronographic Theory of Development, Aging, and Origin of Cancer”, positing a critical role of new hypothetical organelles – chronomeres and printomeres –  in these processes. According to this theory, aging of a multicellular organism is caused by the stepwise programmed loss of chronomeres, whereas senescence of dividing cells is associated with the shortening and loss of printomeres. Both printomeres and chronomeres are small perichromosomal amplificates of the regulatory segments of chromosomal DNA, and they encode regulatory RNAs. Chronomeres are located in neurons of brain’s chronograph, or a specialized clock, which records the lived time in the form of nonrandom changes of body structures. According to the new theory, in the future, the key techniques to postpone organismal aging and to stop tumor growth could be: 1) a stopping of the pacemaker of the biochronograph mechanism, and 2) a forced regeneration, or re-synthesis, of chronomeres and printomeres.

 

 

Some potential interventions to ameliorate degenerative aging

 

balanceSome potential interventions to ameliorate degenerative aging

By Ilia Stambler, PhD

 

The interventions into the degenerative aging process are still in their infancy. A long effortful road will yet need to be traveled from basic research on cell cultures and animal models to effective, safe and widely available human therapies. And many dangers to human health (such as overdose and overstimulation) and many unsubstantiated false claims yet await on this road that need to be guarded against as much as possible. Yet vast promising research is progressing, especially as regards potential pharmaceutical interventions into the aging process.[1] [2] [3] Below are some examples.

1. On November 28, 2015, the FDA approved the testing of Metformin, a decades-old anti-diabetic (blood sugar reducing) medication, as the first drug to treat degenerative aging, rather than particular diseases, due to its capacity to reduce cancers and other morbidities.[4]

2. On November 25, 2015, the FDA approved an adjuvant therapy (developed by Novartis) for a flu vaccine to boost immune response in older persons. This development goes beyond “a drug against a disease” model, but seeks an appropriate regulatory framework to support the underlying health of older persons, using “adjuvant” (i.e. “supportive/additional”) therapy.[5]

3. The immunosuppressant drug Rapamycin, believed to mimic the healthspan extending effects of calorie restriction (CR-mimetic), has produced improvements of energy metabolism, and to extend lifespan and delay aging in mice, and was also effective against particular aging-related diseases, such as Alzheimer’s disease, in human studies. Further research is done on Rapamycin’s analogs – the so called “rapalogs”, potentially with less side effects.[6]

4. By splicing the circulatory systems of animals (mice) together, via the process of “parabiosis”, young blood was shown to have rejuvenating effects on old tissues, including the heart, brain, and muscle tissues, with improved strength and cognitive ability. Some of the implicated rejuvenating substances included: Notch signaling activators, deactivation of the transforming growth factor (TGF)-β that blocks cell division, oxytocin, and Growth Differentiation Factor 11 (GDF11). In September 2014, a clinical trial by Alkahest in Menlo Park, California, became the first to start testing the benefits of young blood and young plasma in older people with Alzheimer’s disease.[7]

5. A new class of drugs – the “senolytics” capable of eliminating senescent cells and the accompanying pathologies – are being developed, in Mayo Clinic, Rochester, Minnesota and elsewhere.[8] Thus the combinations of the “senolytic” drugs Dasatinib and Quercetin proved effective against senescent human cells and in a mouse model. Together these drugs were able to reduce senescent cell burden, extend healthspan and improve physical exercise capacity in old mice, reducing their osteoporosis and other age-related pathologies.[9] Senescent cells can also be eliminated by immunological means, such as vaccines, antibodies and killer T cells.[10]

6. Resveratrol, a natural polyphenolic compound, among other sources found in red wine, has demonstrated the ability to up-regulate Sirtuin 1 (SIRT1) – an acknowledged prolongevity enzyme[11] important for enhanced stress response, cardiovascular protection, improved cognitive function and synaptic plasticity, and suppressing inflammation.[12] SIRT1 expression is generally related to the levels of energy metabolism, as indicated by NAD/NADH levels, which have also become targets for diverse pharmaceutical interventions (NAD replacement therapy).[13]

7. Dichloroacetate and bicarbonate represent a class of compounds and therapies that may have systemic effects on tissue redox and pH state, with broad implications for the aging process and derivative pathologies, such as cancer.[14]

8. Generally, regenerative medicine, using stem cells of various origins to rebuild, “regenerate” or improve the function of worn out and aging organs and tissues, can be promising for combating the degenerative pathologies of aging.[15] Even entire “replacement organs and tissues” can be grown outside of the body – using such methods as growing tissues on biodegradable scaffolds, 3D tissue printing, bioreactors or self-organization — to “replace” the worn out and aging body parts.[16] Yet, very recently a very promising direction in regenerative medicine has emerged – the induction of regeneration within the body by pharmacological means (e.g. using inhibitors of prostaglandin breakdown thus promoting cell proliferation).[17]

9. Of special importance for regenerative medicine against aging-related degeneration is the ability to regenerate the thymus gland (that produces the immune T-cells that play the crucial role for the immune defense). This importance derives from the fact that such an ability could dramatically improve therapy not only for aging-related non-communicable chronic diseases (such as heart disease and neurodegenerative diseases that are strongly related to altered immune response), but also help combat infectious, communicable diseases (like AIDS, Herpes and Influenza) thanks to improved immunity. Such regenerative ability for the thymus was shown by genetic engineering interventions (e.g. using over-expression of the FOXO gene)[18] and even pharmaceutical treatments (e.g.  using the FGF21 hormone).[19]

10. The extension of the telomere end points of the chromosomes, thus increasing the number of cell replications, by such means as genetically engineered overexpression of the telomere-repairing enzyme – telomerase, and even by some pharmacological stimulators of telomerase activity, have been associated with increased lifespan and reduced pathology in animal models.[20] [21] [22]

11. There have been many methods investigated for improving mitochondrial function and cellular respiration. Thus anti-oxidant molecules attached to positively charged ions (cations) have been targeted into mitochondria to eliminate oxidative damage at its origin (the SkQ ions).[23] In another approach, chemical compounds (in particular suppressors of the IIIQsite of the respiratory chain in the mitochondria) have been identified that can block the production of certain free radicals in cells without changing the energy metabolism of these cells.[24] A large additional array of boosters of mitochondrial activity and cellular respiration has been proposed, e.g. methylene blue, the naphthoquinone drug β-lapachone, supplementation with various components of the respiratory oxidative phoshorylation system – such as CoQ10, pyruvate, succinate, vitamins C and K, quercetin, various other anti-acidic, anti-toxic, and anti-oxidant substances.[25]

12. Anti-inflammatory medications have been widely tested to diminish aging-related degenerative pathologies, such as neuro-degenerative pathologies, and to extend healthy lifespan in animal models.[26] But also pro-inflammatory effects have been shown to be important for tissue regeneration.[27]

13. Diverse means are being developed to dissolve macro-molecular (cross-linked) aggregates that “clog” cell machinery. Some approaches include stimulation of cell autophagy that can help remove such aggregates (e.g. by introducing Beclin protein). Various “AGE-breakers” are being developed. These are, as a rule, small molecules capable of breaking “Advanced Glycation Endproducts” (AGE) that are chiefly responsible for the formation of macromolecular aggregates (e.g. glucosepane, one of the most common forms of cross-linked AGE products in collagen). Some of the therapeutic means against cross-linked aggregates include chelators (removing the metal ions that are important for the formation of the cross-links), enzymatic clearance (oxidoreductive depolymerization of the aggregates by enzymes), immunoclearance (using immune mechanisms, e.g. antibodies, to remove the aggregates), etc.[28] Yet, it needs to be noted that macromolecular aggregates, in certain amounts and under certain circumstances, may have a necessary function in the body too.[29] Removing too much of them and in wrong places may do more damage than good.

14. Keeping the body chemistry in balance is hoped to be achieved by supplementing deficient elements in the diet (e.g. vitamins, microelements, other essential nutrients), while eliminating excessive and therefore toxic elements (by such means as chelators, enterosorbents, dietary restriction, enhanced elimination).[30] But what is “the balance”? How much is “too much” or “too little”? The guiding rule is always “The dose makes the poison”.[3] Dietary interventions, that are being tested, include dietary restrictions of various kinds (mainly protein restriction and calorie restriction) that have been associated with extended lifespan in animal models and some health benefits in humans.[31] Also new ways are being sought to enrich the “microbiome” (intestinal bacteria populations) for healthy longevity[32], for example using probiotic diets – the idea that goes back to the origins of scientific aging research, over a century ago.[33]

15. Epigenetics (acquired or heritable changes in gene function without changes in DNA sequence), has been increasingly investigated and manipulated for its effects on aging and aging-related diseases, and their amelioration, at the level of the entire organism as well as particular tissues, for example, using demethylating agents, small interfereing RNAs (siRNAs) and micronutrients as potential therapeutic agents.[34]

16. Interventions into degenerative aging are now beginning to reach the “nano” level. Some of the uses of nanomedicine against degenerative aging include nanoparticles, such as Buckminsterfullerene or “bucky-balls” C60 with assumed antiviral, antioxidant, anti-amyloid, immune stimulating and other therapeutic activities, and some reported lifespan extending results in animal models.[35] Moreover, there even have been announced the first operating medical nanorobots, mainly intended to assist in precise drug delivery, acting as prototypes of artificial immune cells.[36] [37] These nanodevices were mainly intended to eliminate cancer cells, but could also be used to eliminate other types of cells, e.g. senescent cells. In another area of development, oxygenated micro-particles seem to be very promising for life extension, especially in critical conditions, as oxygen deprivation is the main (or even the ultimate) cause of death.[38]

17. Anti-aging and life-extending interventions do not necessarily need to be chemical or biological, but can also be physical, in particular as relates to various resuscitation technologies (hypothermia and suspended animation,[39] oxygenation,[40] electromagnetic stimulation[41]). Such technologies represent probably the most veritable means for life extension, demonstrably saving people from an almost certain death. But similar principles could perhaps be used for more preventive treatments and in less acute cases.

18. It seems to be impossible to speak of “treating” or “curing degenerative aging” without the ability to diagnose this condition and to reliably assess the effectiveness of interventions against it.[42] Hence a wide array of biomarkers and clinical end points are being sought to diagnose degenerative aging and aging-related ill health, and to determine correct “biological age”.[43] Clinically applicable and scientifically grounded diagnostic criteria and definitions for aging may also have profound encouraging implications for the regulation and promotion of research, development, application and distribution of anti-aging and life-extending and healthspan-extending  therapies.[44] [45]

 

Aknowldgedment

I thank Steve Hill and Kevin Perrott for their suggestions regarding the diverse research areas. Any additional suggestions are appreciated.

 

References

[1] Jin K, Simpkins JW, Ji X, Leis M, Stambler I. 2015. The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. Aging and Disease  6, 1-5 http://www.aginganddisease.org/EN/10.14336/AD.2014.1210

[2] Stambler I. 2015. Stop Aging Disease! ICAD 2014. Aging and Disease 6 (2), 76-94 http://www.aginganddisease.org/EN/10.14336/AD.2015.0115

[3] Stambler I. 2014. A History of Life-Extensionism in the Twentieth Century, Longevity History. http://www.longevityhistory.com/

[4] Macdonald F. December 1, 2015. A common diabetes drug will be trialled as an anti-ageing elixir from next year. Research suggests it could help people live to 120. Science Alert

http://www.sciencealert.com/a-common-diabetes-drug-will-be-trialled-as-an-anti-ageing-elixir-from-next-year

[5] Preidt R. November 25, 2015. FDA Approves Flu Shot to Boost Immune Response.Vaccine can be used in seniors, who are often hit hardest by illness. WebMD News from HealthDay.

http://www.webmd.com/cold-and-flu/news/20151125/fda-approves-first-flu-shot-with-added-ingredient-to-boost-immune-response

[6] Richardson A, Galvan V, Linc AL, Oddo S. 2015. How longevity research can lead to therapies for Alzheimer’s disease: The rapamycin story. Experimental Gerontology. 68, 51–58 http://www.sciencedirect.com/science/article/pii/S0531556514003490

[7] Scudellari M. 21 January 2015. Ageing research: Blood to blood. Nature 517 (7535). http://www.nature.com/news/ageing-research-blood-to-blood-1.16762

[8] Wadenov N. November 2, 2011. Purging Cells in Mice Is Found to Combat Aging Ills. New York Times. Based on Darren J. Baker, …, Jan M. van Deursen. 2011, Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders. Nature 479(7372), 232-236.

http://www.nytimes.com/2011/11/03/science/senescent-cells-hasten-aging-but-can-be-purged-mouse-study-suggests.html?_r=0

[9] Yi Zhu et al. 2015. The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644–658.  http://onlinelibrary.wiley.com/doi/10.1111/acel.12344/abstract

[10] Sagiv A, Krizhanovsky V. 2013. Immunosurveillance of senescent cells: the bright side of the senescence program. Biogerontology 14 (6), 617-628 http://link.springer.com/article/10.1007/s10522-013-9473-0

[11] Ledford H. 22 February 2012. Sirtuin protein linked to longevity in mammals. Male mice overproducing the protein sirtuin 6 have an extended lifespan. Nature News. Based on Yariv Kanfi, …, Haim Y. Cohen. 08 March 2012. The sirtuin SIRT6 regulates lifespan in male mice. Nature 483, 218–221. http://www.nature.com/news/sirtuin-protein-linked-to-longevity-in-mammals-1.10074

[12] Maheedhar Kodali, Vipan K. Parihar, Bharathi Hattiangady, Vikas Mishra, Bing Shuai & Ashok K. Shetty. 2015. Resveratrol Prevents Age-Related Memory and Mood Dysfunction with Increased Hippocampal Neurogenesis and Microvasculature, and Reduced Glial Activation. Scientific Reports 5, 8075http://www.nature.com/articles/srep08075

[13] Weintraub K. February 3, 2015. The Anti-Aging Pill. MIT Technology Review.http://www.technologyreview.com/news/534636/the-anti-aging-pill/

[14] Ian F Robey and Natasha K Martin. 2011. Bicarbonate and dichloroacetate: Evaluating pH altering therapies in a mouse model for metastatic breast cancer. BMC Cancer 11, 235 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125283/

[15] Jennifer L. Olson, Anthony Atala, and James J. Yoo. 2011. Tissue Engineering: Current Strategies and Future Directions. Chonnam Med J. 47(1), 1–13 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214857/

[16] Giuseppe Orlando, Shay Soker, Robert J. Stratta, and Anthony Atala. 2013. Will Regenerative Medicine Replace Transplantation? Cold Spring Harb Perspect Med.  3(8), a015693 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214857/

[17] New drug triggers tissue regeneration: Faster regrowth and healing of damaged tissues. Science Daily. June 11, 2015. Based on Yongyou Zhang, et al. 2015 June 12. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 348(6240), aaa2340 http://www.sciencedaily.com/releases/2015/06/150611144438.htm

[18] Living organ regenerated for first time: Thymus rebuilt in mice. Science Daily. April 8, 2014. Based on N. Bredenkamp N., Nowell C. S., Blackburn C. C. 2014. Regeneration of the aged thymus by a single transcription factor. Development 141 (8), 1627 http://www.sciencedaily.com/releases/2014/04/140408115610.htm

[19] Life-extending hormone bolsters the body’s immune function. Science Daily. January 12, 2016. Based on Yun-Hee Youm, Tamas L. Horvath, David J. Mangelsdorf, Steven A. Kliewer, Vishwa Deep Dixit. 2016. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proceedings of the National Academy of Sciences, 201514511 http://www.sciencedaily.com/releases/2016/01/160112093545.htm

[20] Mariela Jaskelioff, …, Ronald A. DePinho. January 6, 2011, first published online on November 28, 2010. Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature, 469, 102-106. Reported in Ian Sample, November 28, 2010. Harvard scientists reverse the ageing process in mice – now for humans, Guardian  http://www.guardian.co.uk/science/2010/nov/28/scientists-reverse-ageing-mice-humans

[21] Bär C and Blasco MA. 2016. Telomeres and telomerase as therapeutic targets to prevent and treat age-related diseases. F1000Research 2016, 5 (F1000 Faculty Rev):89 (doi:10.12688/f1000research.7020.1)http://f1000research.com/articles/5-89/v1

[22] Erez Eitan, …, Esther Priel. 2012. Novel telomerase-increasing compound in mouse brain delays the onset of amyotrophic lateral sclerosis. EMBO Mol Med. 4(4), 313-329 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376858/

[23] Skulachev VP, et al. 2009. An attempt to prevent senescence: a mitochondrial approach. Biochimica et Biophysica Acta, 1787(5), 437-61 http://www.sciencedirect.com/science/article/pii/S0005272808007573

[24] Bender E. September 22, 2015. Stopping free radicals at their source. Novartis Institute for Biomedical Research. Based on Adam L. Orr et al. 2015. Suppressors of superoxide production from mitochondrial complex III. Nature Chemical Biology 11(11), 834-836 https://www.nibr.com/stories/discovery/stopping-free-radicals-their-source

[25] Eric A. Schon and Salvatore DiMauro. 2003. Medicinal and Genetic Approaches to the Treatment of Mitochondrial Disease. Current Medicinal Chemistry, 10, 2523-2533 http://homepages.ihug.co.nz/~Smconnell/Medicinal%20and%20Genetic%20Approaches%20to%20Mitochonrial%20Disease.pdf

[26] Could ibuprofen be an anti-aging medicine? Buck Institute. December 11, 2014. Based on Chong He, et al. 2014. Enhanced Longevity by Ibuprofen, Conserved in Multiple Species, Occurs in Yeast through Inhibition of Tryptophan Import. PLoS Genet 10(12): e1004860 http://www.buckinstitute.org/buck-news/could-ibuprofen-be-an-anti-aging-medicine

[27] Michael Karin and Hans Clevers. 21 January 2016. Reparative inflammation takes charge of tissue regeneration. Nature 529, 307–315 http://www.nature.com/nature/journal/v529/n7586/full/nature17039.html

[28] SENS Research Foundation. A Reimagined Research Strategy for Aging. GlycoSENS: Breaking extracellular crosslinks http://www.sens.org/research/introduction-to-sens-research/extracellular-crosslinks

[29] In defense of pathogenic proteins. January 8, 2016. Science Daily. Based on Juha Saarikangas, Yves Barral. 2015. Protein aggregates are associated with replicative aging without compromising protein quality control. eLife, 2015;4 http://www.sciencedaily.com/releases/2016/01/160108083456.htm

[30] Santos J, Leitão-Correia F, Sousa MJ, Leão C. 2016. Dietary Restriction and Nutrient Balance in Aging. Oxid Med Cell Longev. 2016:4010357 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670908/

[31] Dryden J. September 2, 2015. Drastically cutting calories lowers some risk factors for age-related diseases​​. Healthchannel. Based on Ravussin E, et al. September 2015. A 2-Year Randomized Controlled Trial of Human Caloric Restriction: Feasibility and Effects on Predictors of Health Span and Longevity. Journal of Gerontology: Medical Sciences http://www.healthcanal.com/geriatrics-aging/66558-drastically-cutting-calories-lowers-some-risk-factors-for-age-related-diseases%E2%80%8B%E2%80%8B.html

[32] O’Toole PW, Jeffery IB. 2015. Gut microbiota and aging. Science. 350(6265), 1214-1215 http://science.sciencemag.org/content/350/6265/1214

[33] Ilia Stambler. 2015. Elie Metchnikoff – the founder of longevity science and a founder of modern medicine: In honor of the 170th anniversary. Advances in Gerontology, 28 (2), 207-217, 2015 (Russian) and 5(4), 201-208 (English). http://www.longevityhistory.com/articles/ab15.php

[34] Brunet A, Berger SL. 2014. Epigenetics of aging and aging-related disease. J Gerontol A Biol Sci Med Sci. 69 Suppl 1:S17-20 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4022130/

[35] Tarek Baati, …, Fathi Moussa. 2012. The prolongation of the lifespan of rats by repeated oral administration of [60] fullerene. Biomaterials, 33(19), 4936-4946 http://www.sciencedirect.com/science/article/pii/S0142961212003237

[36] Shawn M. Douglas, Ido Bachelet, George M. Church. 17 February 2012. A Logic-Gated Nanorobot for Targeted Transport of Molecular Payloads. Science, 335 (6070), 831-834 http://science.sciencemag.org/content/335/6070/831

[37] Griffiths S. 18 March 2015. Nanorobots trial to begin in humans: Microscopic DNA devices could be injected into a leukaemia patient in a bid to destroy abnormal cells. Daily Mail http://www.dailymail.co.uk/sciencetech/article-3000904/Nanorobots-trial-begin-humans-Microscopic-DNA-devices-injected-leukaemia-patient-bid-destroy-abnormal-cells.html

[38] Kheir JN, et al. 2012 June 27. Oxygen gas-filled microparticles provide intravenous oxygen delivery. Science Translational Medicine, 4(140):140ra88 https://www.researchgate.net/publication/228089270_Oxygen_Gas-Filled_Microparticles_Provide_Intravenous_Oxygen_Delivery

[39] Bellamy R, et al. 1996. Suspended animation for delayed resuscitation. Critical Care Medicine. 24(2 Suppl):S24-47 http://www.ncbi.nlm.nih.gov/pubmed/8608704

[40] Rogatsky GG, Mayevsky A. 2007. The life-saving effect of hyperbaric oxygenation during early-phase severe blunt chest injuries. Undersea Hyperbaric Medicine 34(2), 75-81 http://archive.rubicon-foundation.org/xmlui/bitstream/handle/123456789/6468/17520858.pdf?sequence=1

[41] NIH/National Institute of Biomedical Imaging and Bioengineering. July 30, 2015. Paralyzed men move legs with new non-invasive spinal cord stimulation. Based on Gerasimenko Yury P., et al. December 2015. Noninvasive Reactivation of Motor Descending Control after Paralysis. Journal of Neurotrauma. 32(24), 1968-1980 http://www.eurekalert.org/pub_releases/2015-07/niob-pmm073015.php

[42] Blokh D and Stambler I. 2015. Information theoretical analysis of aging as a risk factor for heart disease. Aging and Disease, 6 (3), 196-207 http://www.aginganddisease.org/EN/10.14336/AD.2014.0623

[43] Georg Fuellen, et al. December 17, 2015. Living Long and Well: Prospects for a Personalized Approach to the Medicine of Ageing. Gerontology https://www.researchgate.net/publication/287212601_Living_Long_and_Well_Prospects_for_a_Personalized_Approach_to_the_Medicine_of_Ageing

[44] Zhavoronkov A and Bhullar B. 2015. Classifying aging as a disease in the context of ICD-11. Frontiers in Genetics 6, 326. doi: 10.3389/fgene.2015.00326 http://journal.frontiersin.org/article/10.3389/fgene.2015.00326/full

[45] Stambler I. January 1, 2016. Recognizing Degenerative Aging as a Treatable Medical Condition – Policy and Methodology. Longevity for All http://www.longevityforall.org/recognizing-degenerative-aging-as-a-treatable-medical-condition-policy-and-methodology/

 

 

Långt liv

Vi jobbar för ett långt friskt liv för alla invånare genom forskning, folkhälsa, och social aktivism. Vi vill betona vikten av att prioritera den vetenskapliga kampen mot den stora fienden till ett långt friskt liv – åldrandeprocessen. Åldrandeprocessen är roten till de flesta kroniska sjukdomar som drabbar jordens befolkning. Denna process orsakar majoriteten av handikapp, sjukdom och lidande, och måste behandlas därefter. Samhället måste lägga sina resurser för att behandla åldrande precis som övriga sjukdomar. Åldrandeproblemet är allvarligt och hotande. Trots detta ser vi ofta ett total likgiltighet till dess realitet och allvar . Det finns en tendens att ignorera framtiden, att distrahera sig från åldrande och död, och även att presentera åldrande och död på ett missvisande, ursäktande och utopiskt synsätt. Samtidigt, finns det en ogrundad tro att åldrandet är en fullständigt ohanterbar, oundviklig process. Denna ignorans av problemet och den ogrundade känslan av vanmakt hjälper inte till med att förbättra hälsan hos de äldre och deras möjligheter till ett långt friskt liv. Det finns ett stort behov av att presentera problemet med dess fulla allvar och vikt och agera för dess lösning med det bästa av vår förmåga. Vi vill öka allmänhetens medvetande kring problemet med åldrande med de följder som det innebär. Vi vill att allmänheten ska erkänna detta allvarliga problem och lägga våra resurser – ekonomiska, socio-politiska, vetenskapliga, teknologiska och media – till mesta möjliga nytta för att hjälpa den åldrande befolkningen, för möjligheten till ett långt friskt liv. Vi hävdar att mental och själslig mognad och förlängningen av ett långt friskt liv inte nödvändigtvis är samma sak som åldrande och försvagning. Vi kämpar för tillämpningen och ökningen av basal och applicerad biomedicinsk forskning, och även utvecklandet av teknologier, industriella, miljömässiga, kring folkhälsoaspekter och utbildningar, speciellt inriktat på ett långt friskt liv,. Om dessa satsningar ges tillräckligt stöd, så kan de öka den friska livslängden hos den åldrande befolkningen, perioden av produktivitet,de äldres bidrag till utvecklingen av samhället och ekonomin, såväl som deras känsla av mening och livskvalite. Vi förespråkar utvecklandet av vetenskapliga metoder för förlänging av det friska livet, och att detta får mesta möjliga genomslag och det politiska stöd som det förtjänar, inte bara av det grupper av experter utan också av den stora allmänheten.

The 21st Century Cures Act

The 21st Century Cures Act

Summary:

The 21st Century Cures Act (House Resolution 6) is a bi-partisan proposal  introduced by US Congressman Fred Upton (R-MI) and introduced May 19 2015 and assigned to the House Energy and Commerce Committee chaired by Rep. Upton. Representative Diana DeGette as cosponsor and 230 cosponsors, received a favorable vote of 344 – 77 in the House and on July 13, 2015 was sent to the Senate Committee on Health, Labor and Pensions. It has been called a “breakthrough” in bi-partisan politics by none other than former House Speaker Newt Gingrich, and is designed to streamline medical interventions for cures.

 

What Can Be Done Generally:

Provide bi-weekly updates tracking progress of bill through Senate and Executive Office

 

Support recognition of degenerative aging processes as a medical condition, and as the major underlying factor of all aging-related diseases and conditions (incl. cancer, cardiovascular disease, neurodegenerative disease, pulmonary obstructive disease, type 2 diabetes, frailty) hence subject to diagnosis, development and application of “cures” and therefore an indispensable part of the Act, entitled to participate in all its programs.

 

Use it as a rallying call to enlist top researches of aging (from Buck Institute, Barshop Institute, Albert Einstein College of Medicine, Rochester University, University of North Texas Health Science Center, etc. etc) to support our coalition.

 

Key Point A

The 21st Century Cures Act would establish in the U.S. Treasury an NIH and Cures Innovation Fund endowed with $1.86 billion in mandatory funds per year for FY2016 through FY2020 to be disbursed across the following initiatives: biomedical research, cures development, an accelerating advancement program, high-risk high-payoff research, and special funding support for early career researchers. The fund offers encouragement to researchers seeking assurance that lack of money will not represent a prominent roadblock to advancement of their lines of inquiry.

 

What Can Be Done Specifically:

Connect researchers and fellows to appropriate contact persons overseeing CI Fund.

 

Support dedication of funds to translational aging research within the Cures Innovation Fund.

 

Key Point B

The 21st Century Cures Act authorizes annual increases in NIH’s overall budget from $3.1 billion in 2016 to $3.4 billion by 2018, while directing the agency to target resources, through a “strategic plan,” which it is directed to develop to broaden its mission beyond its stronghold in crucial biomedical research and identify contributions to improving U.S. public health through biomedical research.

 

What Can Be Done Specifically:

Learn how it may be possible to become a part of strategic plan, or how one of the fellows and allies could.

 

Include fundamental and translational research of aging into the “strategic plan” of the NIH.

 

Key Point C

It accepts alternatives to multiphase clinical trials in certain circumstances, and permits accelerated approval pathways for certain classes of drugs such as novel antibiotics. Under the new criteria the agency may consider not only randomized clinical trial data, but also, observational studies, registries and therapeutic use as evidence of efficacy for drug and device approvals.

 

What Can Be Done Specifically:

Create brief to distribute to fellows, allies and labs, to enlighten on new opportunities for bringing their work to market.

 

Support inclusion of trials specifically directed for diagnosis and treatment of degenerative aging processes, as underlying causes of aging-related diseases.

 

Support increased transparency and reproducibility of studies as additional proofs of efficacy and thus additional indications for accelerated approval.

 

Support complementary modes of evidence (e.g. comprehensive in silico modeling or integrative models relating different levels of biological complexity) as additional proofs of efficacy and thus additional indications for accelerated approval.

 

Support international collaboration in the development and distribution of cures against aging-related ill health.

 

Key Point D

Over 250 organizations sent a letter of support to Congress.

 

What Can Be Done Specifically:

Contact the person who organized the sign-ons to that letter (or coalition/alliance org) and ask to sign on, and to connect to their contacts OR just go about forming strategic, PR-based partnerships with the biggest organizations listed.

 

In negotiations with the partners in the Act support coalition, urge them to recognize the importance of degenerative aging processes as the main underlying risk factor and often direct cause of all aging-related non-communicable diseases, and as a strong aggravating factor in communicable infectious diseases – and therefore in need of urgent inclusion into the Act.

 

References:

http://managedhealthcareexecutive.modernmedicine.com/managed-healthcare-executive/news/21st-century-cures-act-five-things-know?page=0,3

The critical need to promote research of aging and aging-related diseases to improve health and longevity of the elderly population. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4306469/

 

Provided by Global Healthspan Policy Institute

 

დღეგრძელობა

  • დღეგრძელობა

    ჩვენ ვიღწვით სრულიად მოსახლეობის ჯანსაღი დღეგრძელობის განვითარებისთვის მეცნიერული კვლევების, ჯანმრთელობის დაცვის, პროპაგანდის და სოციალური აქთიურობების დახმარებით. ჩვენ მკაფიოთ გამოვხატავთ, რომ ჯანსაღი დღეგრძელობის მთავარ მტერს – დაბერებას- გამოვუცხადეთ ბრძოლა!

    დაბერების პროცესი არის ფუძე და ფუძე უმეტესი ქრონიკული დაავადების, რომელიც ადამიანებს ტანჯავს. ის ავსებს ინვალიდობისა და სიკვდილიანობის უდიდეს წილს და მოითხოვს შესაბამის მკურნალობას. ყველამ უნდა გამოვიჩინოთ ძალისხმევა, რომ სიბერის მკურნალობა შესაძლებელი გახდეს ისევე, როგორც სხვა დაავადებები.

    დაბერების პრობლემა თვალსაჩინო საფრთხეა. ამის მიუხედავად ხშირად ვაწყდებით მის მივიწყებას რეალობის და სერიოზულობის მიუხედავად. საზოგადოებაში დამკვიდრებულია მომავლის იგნორირების ტენდენცია რათა ადამიანების გონებამ ყურადღება არ მიაქციოს სიკვდილს და დაბერებას. მეტიც, დაბერება და სიკვდილი უტოპიურ კონტექსტში განიხილება. გავრცელებულია აზრი, რომ “ბუნებრივი” დაბერება სრულიად უმართავია და გარდუვალი. ეს პრობლემაზე თვალების დახუჭვაა. ასეთი უსაფუძვლო უძლურების პოზიცია ხელს არ უწყობს ხანდაზმული ადამიანების მდგომარეობის გაუმჯობესებას და ჯანსაღი დღეგრძელობის მიღწევას. აუცილებლია დაბერების პრობლემის მნიშვნელობის სრული ხარისხით წარმოჩინება და მისი გადაჭრისთვის მოქმედება.

    მოგიწოდებთ სიბერის პრობლემის გათვითცნობიერების ხარისხი გაზარდოთ საზოგადოებაში.. ვაღიაროთ ამ პრობლების სერიოზულობა, არ დავიშუროთ ძალისხმევა და რესურსები – ეკონომიკური, სოციალური, პოლიტიკური, მეცნიერული, ტექნოლოგიური, მასმედიური – იმისთვის, რომ მაქსიმალურად გაიოლდეს ჯანსაღი დღეგრძელობის მიღწევა. ჩვენ ვნერგავთ იდეას, რომ გონებრივი და სულიერი განვითარება, ჯანსაღი დღეგრძელობა არ არის სიბერის და გაუარესების სინონიმები.

    ჩვენ ვაცხადებთ, რომ მხარს ვუჭერთ ფუნდამენტალური და გამოყენებითი ბიომედიცინური კვლევების წარმოებას და მათ დაჩქარებას. ასევე მხარს ვუჭერთ ტექნოლოგიურ, სამეწარმეო, ეკოლოგიურ, ჯანდაცვით, საგანმანათლებლო ღონისძიებებს, რომლებიც მიმართულია ჯანსაღი დღეგრძელობის მისაღწევად. ვთვლით, რომ საკმარისი მხარდაჭერის პირობებში შესაძლებელია ხანდაზმულთა სიცოცხლის გახანგრძლივება, მათი სიცოცხლის ხარისხის შეცლა, რაც საზოგადოების და ეკონომიკის განვითარებას წაადგება და მათ სიამოვნებას მოუტანს, სიცოცხლეს გაუხალისებს და ახალ მიზნებს გაუჩენს.

    ჩვენ ვაცხადებთ, რომ ჯანსაღი დღეგრძელობისთვის მეცნიერული კვლევების განვითარება საჭიროებს მაქსიმალურ საზოგადოებრივ და პოლიტიკურ მხარდაჭერას. ეს პრობლემა იმსახურებს არა მხოლოდ პროფესიულ, არამედ სრულიად საზოგადებრივ ყურადღებას.

     

    See further materials from Georgia Longevity Alliance http://www.longevity.ge/

South Korea – 2007 – The law proposal for the support of scientific and technological research of aging

South Korea – 2007 – The law proposal for the support of scientific and technological research of aging

In Korean:

노화과학기술연구촉진법

(Editor’s note: Please see the The Korean original. Corrections for the English translation below are welcome!)

The law proposal to support scientific and technological research of aging includes establishing a main plan and monitoring program for the proposed law (Articles 2 – 5), the creation and support of a scientific and technological research council in the field of aging, and creation and support of a scientific and technological research committee on aging, their structure and administration (Articles 6 – 12), support and supervision for the manufacturing of  new technological products (Article 14), clinical trials and experimental testing (Articles 14, 15), etc.

The law proposal for the support of scientific and technological research of aging

  1. Purpose

The purpose of this law is to provide the basis for the wide support of scientific and technological research of aging, to ensure the effective prioritizing of this research, facilitating the technological development and commercial utilization of its results, as well as the development of methods to improve the health of the nation and the state of the economy.

  1. Definitions

Research of aging, defined under this law, is scientific and technological biomedical research aimed to elucidate the mechanisms of aging with the purpose to achieve healthy and active longevity, prevent and treat age-related diseases due to the aging process, promote active longevity with good functional abilities, strong physical and mental health of the aged. The research of aging involves a multidisciplinary framework of societal, educational, as well as scientific, technological and methodological areas.

  1. Scope

All research of aging must be performed under this Law, except for cases particularly stipulated under other laws containing specific rules.

  1. Responsibilities of the government

(1).  It is the responsibility of the government to establish and actively pursue a main plan for the development and support of research of aging.

(2). All legal entities, such as universities, research institutes, and companies, and individuals involved in research of aging, must cooperate in developing and pursuing the policy and the main plan to support research of aging, in accordance to paragraph 1.

  1. Developing the main plan to support research of aging

(1). The appointed central Administration Agency (Administration Center) for the research of aging within the Ministry of Science and Technology must prepare a document containing the goals and directions for research of aging, as well as a planned annual schedule of research of aging, and a report on the research of aging in the previous year, and must submit it to the Minister of Science and Technology.

(2) The minister, based on the plans provided by the Administration Center as of paragraph 1, must issue the main plan (hereafter “the plan”) for research of aging, which, after adjustments suggested by the appointed Research Council on Aging (as of Article 7 below), must be submitted to the Administration Center. The procedure of changing the main plan is the same.

(3). The plan referred to in paragraph 2 must include:

  1. The long-term and short-term purpose and content of the research on aging;
  2. Ways to attract investors and plans to use funds for research of aging.

iii. An analytic plan for the development and utilization of aging research in terms of education, science, engineering and technology, agriculture, information, environment, fisheries, etc.

  1. A specification of human resources and specialists needed for research of aging and plans for their training and recruitment.
  2. The plan for preserving and utilizing the results of research of aging.
  3. Other necessities and relevant studies needed to support research of aging.
  4. Implementation of the action plan for the support of research of aging

 

(1). Annually, the Administration Center will supervise and report to the Minister of Science and Technology on the implementation of the plan for research of aging.

(2). Head of the Administration Center must discuss in advance with the Minister of Science and Technology regarding measures intended to implement the plan for research of aging.

(3). When necessary, the Minister of Science and Technology may establish basic guidelines for the implementation of the plan via prior consultation with the head of theAdministrationCenter.

(4). The development and implementation of the plan must be approved by a presidential decree.

  1. Council for the support of scientific and technological research of aging

 

(1). For the deliberation on matters pertaining to the support of research of aging, the special advisory Council for the support of research of aging (hereafter “the Council”) shall be established.

(2) The Council shall deliberate on the following matters:

  1. Developing the main plan for the support of research of aging, and the consequent formulation of relevant policies, coordination and supervision of their implementation.
  2. Increasing the budget and investments for long-term technological and scientific research of aging.

iii. Establishing the requirements and developing plans for attracting professional human resources to the research of aging according to specialty, category, fields and projects, formulating the recruitment policy, supervising and adjusting the implementation of the plans.

  1. Developing plans for the preservation and utilization of the results of research of aging, coordination and supervision of their implementation.
  2. Providing additional information regarding resources needed for research of aging, as considered appropriate by the Council head.

(3). The Council shall consist of the head (Chairman) and not more than 20 members.

(4). The chairman of the Council shall be appointed by the Minister of Science and Technology, and shall coordinate between theAdministrationCenter officials, the scientific community (academics, research institutes), and industry professionals.

(5). The Council must include 6 members of academia, 3 representatives of research institutes, and 2 representatives of industry.

(6). The structure and operational requirements for the Council will be established by a Presidential Decree.

  1. Working Committee for the support of scientific and technological research of aging

(1) The Working Committee (“the Committee”) shall be established to conduct practical tasks assigned by the Council and approved by the Minister of Science and Technology.

(2). The Committee shall consist of governmental officials of the Administration Center, members of academia and research institutes, and industry professionals working in research of aging.

(3). The Committee structure and requirements for its effective operation will be established by a Presidential Decree.

  1. Increasing the investment in research of aging

(1) It is the duty of the government, as stipulated in Article 5, paragraph 2 (ii), to support the expansion of investments into research of aging, according to the main plan and the scope of the budget.

(2). The Minister of Science and Technology is responsible for developing the annual investment plan for research of aging and, after consultation with the Council, it must be submitted to the National Science and Technology Council.

  1. Scientific and technological cooperation

The government must promote international cooperation in aging research and related technological development, and attract foreign experts to work in this area.

  1. Promotion of cooperative research and development

The government will actively promote collaborative research projects involving academic and research institutes and industry in order to jointly develop scientific and technological capabilities for the purposes of research of aging.

  1. Support of industrial production

The government will facilitate the manufacturing of new products, created as a result of research of aging.

  1. Collection and dissemination of technical information

The government will collect and widely spread information on research of aging. At the same time, the various agencies involved in this area will be recruited to assist the government in collecting and spreading information on the subject.

  1. Promotion measures for research of aging

To increase the efficiency of research of aging, the relevant ministries will undertake the following measures:

(1). The Minister of Education will support training in the field of research of aging and provide incentives to educators in this field.

(2). The Minister of Science and Technology will be chiefly responsible for developing the Main Plan for the Support of Research of Aging, will direct its design and implementation, collection of resources, facilitation of information exchange and cooperation in the field, development of new related technologies, preservation and utilization of research results in practice, promotion of public access, support and education in the field, assisting agencies involved in research of aging.

(3). Minister of Agriculture will promote the experimental research of aging  related to the development of agriculture, animal husbandry and forestry, and will advance the translation of this research into related technologies followed by their wide application in production.

(4). Minister of Commerce, Industry and Energy Resources will facilitate the creation of new manufacturing processes, engineering applications and industrial deployment of technologies originating in research of aging.

(5). Minister of Information and Communication will develop information and communication technologies for research of aging, promote the dissemination and practical application of the gathered knowledge.

(6). Minister of Health and Welfare will ensure the application of the results of research of aging in health care practice, will support the development and application of biomedical technologies based on this research.

(7). Minister of the Environment will ensure the application of research of aging in the related fields of environmental protection and public health, will contribute to the wide introduction of improved environmental and public health technologies and utilities originating in research of aging.

(8). Minister of Maritime Affairs and Fisheries will promote studies related to research of aging, and facilitate their translation into advanced fishery, seafood and other derived production technologies.

  1. Testing and safety

(1). The government must supervise the manufacturing, testing and safety of products originating from research of aging.

(2). The criteria for effective testing and safety will be determined by a Presidential Decree.

  1. Procedures for planning and conducting experiments

(1). To promote the scientific research and industrial production in the area of aging research, the government must develop procedures for planning and conducting experiments.

(2). In accordance to paragraph (1), guidelines must be established to ensure biological safety, prevention of adverse effects, and avoidance of ethical problems that may arise as a result of scientific research and industrial production originating from research of aging.

  1. Establishment of research institutes.

(1). In order to support research of aging, as well as utilize its results in scientific, technological and industrial development, special institutes for research of aging will be established that will work in close cooperation with industry. The government will supervise and support the establishment of such research institutes.

(2). The special research institutes established in accordance with paragraph (1) shall operate under the provisions of this Law.

Note: This Law will enter into force from the date of its publication.

 

Degenerative Aging as a Medical Condition

whologo Degenerative Aging as a Medical Condition

By Ilia Stambler, PhD

Summary of issue: There has been recently an intensifying discussion among longevity researchers and advocates about the inclusion of the Degenerative Aging Process as a recognized and treatable medical condition, that would include the systemic factors that contribute to diseases and frailty.

The underlying, apparently plausible rationale for this suggestion is that the recognition of degenerative aging as a treatable medical condition would enable the existing legal frameworks to better tackle diseases and conditions that arise from the aging process from a preventative healthcare model. In particular, pharmaceutical, biomedical and wellness industry could then develop for market quickly new and existing preventative medications, biomedical technologies and regimens, that would decrease long-term healthcare costs. Moreover, such a recognition would open up new public funding for new pharmaceutical and biomedical research and development

What can be done generally:

Degenerative aging needs to be recognized as a diagnosable and treatable medical condition, starting with the appropriate WHO frameworks, setting the global standards for disease definitions. Yet, the methods of achieving this recognition with the WHO framework may vary.

This issue must become a subject of massive and pluralistic consultation of scientists and other stakeholders. An initial deliverable could be a collection of papers and expert opinions dedicated to the subject. With this evidential and expert basis and publication, it may be expedient to develop more precise policy recommendations and approaches for further consultation with the relevant WHO departments and affiliates, such as the Global Burden of Disease (GBD) program, the WHO Multi-Country Studies Unit, the WHO Collaborating Centre on International Longitudinal Studies of Gender, Ageing and Health, the developers of the ICD and ICF, WHO Department of Aging and Lifecourse, in particular the GSAP, WHO Program on Non-communicable Diseases and their Risk Factors, UN NGO Committee on Aging, UN Department of Economic and Social Affairs – Division for Social Policy and Development, implementation agencies of the UN Sustained Development Goals (esp. SDG3 on healthcare)  and other relevant authorities.

http://www.who.int/entity/en/

 

 

Local heterogeneity of basal cells of the epidermis

Alexander Khalyavkin

Local heterogeneity of basal cells of the epidermis

 

Izvestia Akademii Nauk SSSR. Seria Biologicheskaya. 5, 778-780, 1982.

 

(Bulletin of the USSR Academy of Sciences. Biology Series. Vol. 5, pp. 778-780, 1982)

 

Alexander Khalyavkin

In Russian: Локалная гетерогенность базальных клеток эпидермиса.

Khalyavkin Local Heterogeneity of Basal Epidermis Cells 82 5

 

 

Abstract:

We have critically analyzed the concept that posits local heterogeneity of basal cells of the epidermis, namely their separation into stem cells and cells that started differentiation. We show that the experimental data on which this concept is based, can be interpreted within the framework of the classical scheme of keratinocyte histogenesis, according to which all basal cells are stem cells and their heterogeneity with reference to several attributes can be related to their different stages within the cell cycle.

 

A series of experimental data, obtained within the last years, indicated the presence of two different types of cells within the population of the basal cells of the epidermis, namely basal stem cells and basal cells committed to differentiation, which differ in their ability for proliferation and differentiation (Potten, Hendry, 1973; Krieg et al., 1974; Marks, 1976; Potten et al., 1979; Potten, 1981). The present article analyzes the justification for this concept which is proposed on the basis of experiments studying clonogenic properties of basal cells and their sensitivity to the effect of G1-Chalone (Potten, Hendry, 1973; Marks, 1976).

 

In radio-biological experiments studying clonogenicity of basal cells in the epidermis of irradiated animals, there was registered the number of colonies formed after certain times following different doses of radiation exposure. Under low doses, there were many surviving cells, the colonies merged and their number was impossible to determine. Therefore the initial number of clonogenic cells was estimated indirectly by extrapolating the data obtained to zero radiation dose, while taking into account the possibility of an initial shoulder in the dose-effect relation. The number of clonogenic basal cells, estimated this way, was much less than the general number of basal cells. This led to the hypothesis that only a part of basal cells are clonogenic stem cells, while the rest are their more differentiated progeny (Potten, Hendry, 1973). This concept was developed in the works studying the effects of exposure of basal cells to the endogenous tissue-specific inhibitor of proliferation – the epidermal G1-Chalone (Krieg et al., 1974, Marks, 1976). These experiments showed that the actively proliferating epidermis (neonatal skin, regenerating skin and skin subjected to tumor promoters) demonstrates reduced sensitivity to G1-Chalone as compared to normal adult epidermis. Within the framework of the concept under consideration, this was explained by suggesting that the basal cells of actively proliferating epidermis contain a larger proportion of stem cells presumably insensitive to the effect of G1-Chalone (Krieg, et al., 1974; Marks, 1976).

 

Thus, based on the different sensitivity to the influence of G1-Chalone and based on experiments studying colony formation in epidermis of irradiated animals, a concept was advanced suggesting the attribution of basal cells to two populations: stem cells-progenitors and their progeny committed to differentiation (Potten, Hendry, 1973; Marks, 1976). This means that, instead of the known histogenic series of stages of keratinocyte maturation (the basal cell → spinous cell → granular cell, etc.), the following modification of this scheme is proposed: the basal stem cell → the basal cell that started differentiation → spinous cell → granular cell, etc. This modified scheme is further supported by the data regarding colony formation of epidermal cells in culture. It is known that the number of colonies formed is much less than the number of seeded basal cells (Rheinwald, Green, 1977). This also seems to indicate that not all basal cells are clonogenic stem cells.

 

However, it is possible that the observed differences in the properties of basal cells are the results of other causes, namely the heterogeneity of their positioning within the cell cycle.

 

It is known that a part of basal cells is outside the mitotic cycle (Fukuda et al. 1978). This state is termed “proliferative rest” i.e. Phase G0 (Lajtha, 1963) or Phase R1 (Epifanova, Terskikh, 1968; Terskich, 1973). The rest of the cells undergo different stages of the mitotic cycle. Insofar as the resting cells are more resistant to external influences than the proliferating cells (Terskich, 1973), the dependence of the number of colonies formed on high doses of irradiation can reflect the radio-sensitivity of resting basal cells. Therefore the extrapolation of this dependence to the zero dose, taking into account the initial shoulder, gives the value equal to the number of basal cells that are found outside the mitotic cycle. Clearly, their number should be less than the general number of basal cells. This can also explain the different ability of basal cells for colony formation in culture. It is assumed that the signal for the transition of basal cells to the path of irreversible differentiation is their detachment from the dermo-epidermal boundary (Flaxman 1972). Therefore, when preparing their reseeding into culture, basal cells are detached from dermal substrate, a part of them, found in G0 state, begin irreversible differentiation and are unable to form colonies. The rest of the cells, found in the mitotic cycle, before transition to differentiation, must complete it. However, during the time of the cycle, their majority gets to precipitate in the culture vessel, attach to the appropriate substrate and therefore is able to form colonies. Hence, an increase of the time interval between the detachment of basal cells form dermal substrate and their placement in the culture on the feeder fibroblast layer, leads to a reduction in the number of colonies formed, while an increase of the proportion of proliferating cells of the epidermis raises this number (Rheinwald, Green, 1977).

 

In order to explain the mechanism of cell transition to the state of proliferative rest, it was suggested that the cells are affected by tissue-specific inhibitors of the mitotic cycle (Bullough, 1963, Lajtha, 1969). The cells can reside in the resting state for a prolonged time and enter the mitotic cycle under the influence of an inductive stimulus (Lajtha, 1969; Smith, Martin, 1973). It is assumed that at any time, under constant conditions, the mitotic cycle is entered by the same proportion of the remaining resting cells (Smith, Martin, 1973). Apparently, the proliferation starts in cells in which the stimulating signal prevails over the inhibiting signal. If assuming that the stationary distribution of resting cells according to the inhibiting signal value, created by the chalones, is nearly Gaussian bell-shaped curve, then the proportion of cells entering the mitotic cycle under the inductive stimulus will be determined by the area beneath the distribution curve, limited on the right by the inhibiting signal value, equal to the stimulating signal value (the inductive stimulus). The addition of chalones will shift the distribution to the right, hence the proportion of cells entering the cycle will diminish. The ratio of the proportion of cells entering the mitotic cycle after the addition of chalones to the proportion of cells entering the cycle without the addition of the chalone, reflects its inhibiting action. The lower this ratio, the more expressed is the chalone’s inhibiting action. These considerations explain why the inhibiting activity of the chalones is better expressed in a cell population subjected to the influence of a small inductive stimulus. Therefore there is no need to adduce the hypothesis about the larger proportion of stem cells presumably insensitive to the effect of chalones, in an actively proliferating population of basal cells. Also the very suggestion about the insensitivity of stem cells to chalones is quite vulnerable (Krieg et al. 1974; Marks 1976).

 

Thus the present analysis allows us to conclude that, despite the attraction of the concept that only a part of basal cells are stem cells, it would be premature to accept it as a final conclusion. This is because the experimental facts, lying at the foundation of that concept, can be explained by the heterogeneity of basal cells with reference to their position in the cell cycle.

 

In conclusion, we would like to note that the study of colony formation in a culture of epidermal cells, obtained from irradiated animals, would allow the evaluation of the real character of the dose-effect dependence under low irradiation doses. This could serve as one of the proofs or refutations for the correctness of the concept under consideration.

 

 

References:

 

Епифанова О.И., Терских В.В. Периоды покоя и активной пролиферации в жизненном цикле клетки. – Ж. Общ. Биол. 1968б т. 29. № 4, с. 392. (Epifanova O.I. Terskich V.V. Period of Rest and active proliferation in cell life cycle. Journal of General Biology – in Russian, vol. 29, no. 4, p. 392, 1968).

Терских В.В. Периоды покоя в нормальных и малигнизированных клетках. – В кн. Клеточный цикл. М. Наука 1973, с. 165. (Terskich V.V. Periods of rest in normal and malignant cells, in Cell Cycle, Nauka, Moscow, 1973, p. 165).

Bullough W.S. Analysis of the life cycle in mammalian cells. – Nature, 1963, v. 199, No. 4896, p. 859.

Flaxman B.A. Replication and differentiation in vitro of epidermal cells from normal skin and from benign (psoriasis) and malignant (basal cell cancer) hyperplasia. – In Vitro, 1972, v. 8, No. 3, p. 327.

Furuda M., Okamura K, Fujita S, Bohm M, Rohbach R, Sandritter W. The different stem cell populations in mouse epidermis and lingual epithelium. – Path. Res. Pract., 1978, v. 163, No. 3, p. 205.

Krieg L, Kuhlmann I, Marks F. Effect of tumor-promoting phorbol esters and acetic acid on mechanisms controlling DNA synthesis and mitosis (chalones) and on the biosynthesis of histidine-rich protein in mouse epidermis. – Cancer Res. 1974, v. 34, No. 11, p. 3135.

Lajtha L.G. On the concept of the cell cycle. – J. Cell Compar. Physiol., 1963, v. 60, No. 2, Suppl. 1, p. 143.

Lajtha L.G. Kinetic models of hemopoietic stem cell population. – Hemic cells in vitro, 1969, v. 4, p. 14.

Marks F. Epidermal growth control mechanisms hyperplasia, and tumor promotion in the skin. – Cancer Res. 1976, v. 36, No. 7, part 2, p. 2636.

Potten C. S. Cell replacement in epidermis (keratopoiesis) via discrete units of proliferativation. – Int. Ev. Cyt. 1981, v. 69, p. 271.

Potten C.S., Hendry J.H. Clonogenic cells and stem cells in epidermis. – Intern. J. Radiat. Biol, 1973, v. 24, No. 5, p. 537.

Potten C.S. Schofield R, Lajtha L.G. A comparison of cell replacement in bone marrow, testis and three regions of surface epithelium. – Biochem. Biophys. Acta, 1979, v. 560, No. 2, p. 281.

Rheinwald J.G. Green H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. – Nature, 1977, v. 265, No. 5593, p. 421.

Smith J.A., Martin L. Do cell cycle? – Proc Natl. Acad. Sci. USA, 1973, v. 70, No. 4, p. 1236.

 

Institute of Chemical Physical – The USSR Academy of Sciences, Moscow

 

Arrived to the editorial office

3.XI.1981

 

Khyalyavkin A.V.

The local heterogeneity of the basal cells of epidermis

 

Institute of Chemical Physics, Academy of Sciences of the USSR, Moscow

 

The critical analysis of the concept, postulating the subdivision of the basal cells of the epidermis into the stem cells and the cells at the beginning of the differentiation is given. It was shown that the experimental data, providing the basis of the concept, can be interpreted within the limits of the classical scheme of keratinocyte’s histogenesis, according to which all basal cells are know as stem cells, but their heterogeneity in a number of properties can be related with the different place in the cellular cycle. The experiment, the results of which can be used as the argument in favor of one of the alternative concepts, is suggested.

 

 

In Russian:

Локалная гетерогенность базальных клеток эпидермиса.

Khalyavkin Local Heterogeneity of Basal Epidermis Cells 82 5

 

УДК 576.321.34

Халявкин А.В.

Локальная гетерогенность базальных клеток эпидермиса.

 

Проведен критический анализ концепции, постулирующей локальную гетерогенность базальных клеток эпидермиса, которая заключается в подразделении их на стволовые клетки и клетки, приступившие к дифференцировке. Показано, что экспериментальные данные, лежащие в основе этой концепции, могут быть интерпретированы в рамках классической схемы гистогенеза кератиноцита, согласно которой все базальные клетки являются стволовыми, а их гетерогенность по ряду свойств может быть связаны с различным положением в клеточном цикле.

 

Ряд экспериментальных данных, полученных в последние годы, привел к представлении о наличии в популяции базальных клеток эпидермиса двух различных типов клеток – стволовых базальных клеток и коммтированных к дифференцировке (Potten, Hendry, 1973; Krieg et al. 1974; Makrs, 1976; Potten et al. 1979; Potten 1981). В настоящем сообщении анализируется обоснованность этой концепции, высказанной на основе экспериментов по изучению клоногенных свойств базальных клеток и их чувствительности к действию G1-кейлона (Potten, Hendry, 1973; Marks, 1976).

 

В радиобиологических экспериментах по изучению клоногенности базальных клеток в эпидермисе облученных животных регистрировалось число колоний, образовавшихся спустя определенное время после действия разных доз облучения. При низких дозах выживших клеток было много, колонии сливались, и их количество определить было невозможно. Поэтому начальное число клоногенных клеток оценивалось косвенно экстраполяцией полученных данных к нулевой дозе облучения с учетом возможного начального плеча на зависимости доза – эффект. Оцененное таким образом число клоногенных базальных клеток оказалось гораздо меньше общего числа базальных клеток. Это дало повод предположить, что только часть базальных клеток является стволовыми (Potten, Hendry, 1973). Данная концепция получила развитие в работах по изучению действия на базальные клетки эндогенного тканеспецифического ингибитора пролиферации – эпидермального G1-кейлона (Krieg et al., 1974, Marks, 1976). В этих опытах было показано, что активно пролиферирующий эпидермис (неонатальная кожа, регенерирующая кожа и кожа, находящаяся под воздействием опухолевого промотера) проявляет пониженную чувствительность к действую G1-кейлона в сравнении с нормальным эпидермисом взрослого. В рамках рассматриваемой концепции это объяснялось тем, что базальные клетки активно пролиферирующего эпидермиса содержат большую долю стволовых клеток, предположительно нечувствительных к действию G1-кейлона (Krieg et al., 1974, Marks, 1976).

 

Таким образом, на основании различной чувствительности к действию G1-кейлона и на основании экспериментов по изучению колониеобрзования в эпидермисе облученных животных была выдвинута концепция о принадлежности базальных клеток к двум популяциям: стволовых клеток-предшественников и их потомков, коммитированных к дифференцировке (Potten, Hendry, 1973 Marks, 1976). Это означает, что вместо известного гистогенетического ряда стадий созревания кератиноцита (базальная клетка ->шиповатая->зернистая и т.д) предполагается следующая модификация этой схемы: базальная стволовая клетка –< базальная клетка, приступившая к дифференцировке –> шиповатая –> зернистая и т.д. В пользу такой модифицированной схемы можно привести и данный по колониеобразованию эпидермальных клеток в культуре. Известно, что число образуемых колоний гораздо меньше числа высеваемых базальных клеток (Rheinwald, Green, 1977). Это как будто бы тоже говорит за то, что не все базальные клетки являются стволовыми клоногенными клетками.

Однако возможно, что наблюдаемые различия в свойствах базальных клеток являются следствием других причин, а именно гетерогенность по положению в клеточном цикле.

Известно, что часть базальных клеток находится вне митотического цикла (Fukuda et al, 1978). Это состояние называется пролиферативным покоем, фазой G0 (Lajtha, 1963) или фазой R1 (Епифанова, Терских, 1968; Терских, 1973). Остальные клетки проходят различные стадии митотического цикла. Поскольку покоящиеся клетки более резистентны к внешним воздействиям, чем пролифирирующие (Терских, 1973), зависмость числа образованных колоний от высоких доз облучения может отражать радиочувствительность покоящихся базальных клеток. Поэтому экстраполяция этой зависимости к нулевой дозе с учетом начального плеча даст величину, равную числу базальных клеток, находящихся вне митотического цикла. Ясно, что их число должно быть меньше общего числа базальных клеток. Этим же можно объяснить и различную способность базальных клеток к колониеобразованию в культуре. Считается, что сигналом для перехода базальных клеток на пусть необратимой дифференцировки является их отрыв от дермо-эпидермальной границы (Flaxman, 1972). Поэтому, когда для подготовки к пересеву их в культуру базальные клетки отделяются от дермальной подложки, часть из них, находящаяся в состоянии G0, начинает необратимую дифференцировку и не способна образовывать колонии. Остальные клетки, находящиеся в митотическом цикле, до перехода в дифференцировку должны завершить его. Однако за время прохождения цикла большинство из них успевает осесть в сосуде для культивирования, закрепиться на соответствующем субстрате и поэтому способно образовывать колонии. Таким образом, увеличение интервала времени между отделением базальных клеток от дермальной подложки и помещением их в культуру на фидерный слой фибробластов приводит к уменьшению количества образуемых колоний, а повышение доли пролиферирующих клеток эпидермиса увеличивает это количество (Rheiwald, Green, 1977).

 

Для объяснения механизма перехода клеток в состоянии пролиферативного покоя было предложено, что на клетки действуют тканеспецифические ингибиторы митотического цикла (Bullough, 1963; Lajtha, 1969). Клетки могут находиться в периоде покоя длительное время и вступать в митотический цикл под влиянием индуктивного стимула (Lajtha, 1969; Smith, Martin, 1973). Считается, что каждый момент времени при постоянных условиях в митотический цикл вступает одна и та же доля оставшихся покоящихся клеток (Smith, Martin, 1973). Видимо, начинают пролиферацию те из них, у которых стимулирующий сигнал превалирует над ингибирующим. Если предположить, что стационарное распределение покоящихся клеток по величине ингибирующего сигнала, создаваемого кейлоном, близко к колоколообразной кривой, то доля клеток, вступающих в митотический цикл под воздействием индуктивного стимула, определится площадью под кривой распределения, ограниченной справа величиной ингибирующего сигнала, равной величине стимулирующего сигнала (индуктивного стимула). Добавление кейлона сместит распределение вправо, поэтому доля клеток, входящих в цикл, уменьшится. Отношение доли клеток, входящих в митотический цикл после добавления кейлона к доле клеток, входящих в митотический цикл после добавления кейлона к доле клеток, входящих в цикл без добавления кейлона, отражает его ингибирующее действие. Чем это отношение ниже, тем ингибирующее действие кейлона выражено больше. Из этих рассуждений видно, почему ингибирующая активность кейлона лучше проявляется в популяции клеток, находящихся под воздействием небольшого индуктивного стимула. Поэтому нет никакой необходимости привлекать гипотезу о большей доле стволовых клеток, предположительно не чувствительных к действию кейлона, в активно пролиферирующей популяции базальных клеток. Достаточно уязвимо и само предположение о нечувствительности стволовых клеток к кейлону (Krieg et al., 1974; Marks, 1976).

 

Таким образом, проведенный анализ позволяет заключить, что, несмотря на привлекательность концепции о том, что только часть базальных клеток является стволовыми, окончательность такого вывода была бы преждевременной. То следует из того, что экспериментальные факты, на которых построена данная концепция, могут объясняться гетерогенностью базальных клеток по их положению в клеточном цикле.

 

В заключение отметим, что изучение колониеобразования в культуре эпидермальных клеток, взятых от облученных животных, позволило бы судить об истинном характере зависимости доза – эффект в области низких доз облучения. Это могло послужить одним из доказательств или опровержения справедливости рассматриваемой концепции.

 

Литература

Епифанова О.И., Терских В.В. Периоды покоя и активной пролиферации в жизненном цикле клетки. – Ж. Общ. Биол. 1968б т. 29. № 4, с. 392.

Терских В.В. Периоды покоя в нормальных и малигнизированных клетках. – В кн. Клеточный цикл. М. Наука 1973, с. 165.

Bullough W.S. Analysis of the life cycle in mammalian cells. – Nature, 1963, v. 199, No. 4896, p. 859.

Flaxman B.A. Replication and differentiation in vitro of epidermal cells from normal skin and from benign (psoriasis) and malignant (basal cell cancer) hyperplasia. – In Vitro, 1972, v. 8, No. 3, p. 327.

Furuda M., Okamura K, Fujita S, Bohm M, Rohbach R, Sandritter W. The different stem cell populations in mouse epidermis and lingual epithelium. – Path. Res. Pract., 1978, v. 163, No. 3, p. 205.

Krieg L, Kuhlmann I, Marks F. Effect of tumor-promoting phorbol esters and acetic acid on mechanisms controlling DNA synthesis and mitosis (chalones) and on the biosynthesis of histidine-rich protein in mouse epidermis. – Cancer Res. 1974, v. 34, No. 11, p. 3135.

Lajtha L.G. On the concept of the cell cycle. – J. Cell Compar. Physiol., 1963, v. 60, No. 2, Suppl. 1, p. 143.

Lajtha L.G. Kinetic models of hemopoietic stem cell population. – Hemic cells in vitro, 1969, v. 4, p. 14.

Marks F. Epidermal growth control mechanisms hyperplasia, and tumor promotion in the skin. – Cancer Res. 1976, v. 36, No. 7, part 2, p. 2636.

Potten C. S. Cell replacement in epidermis (keratopoiesis) via discrete units of proliferativation. – Int. Ev. Cyt. 1981, v. 69, p. 271.

Potten C.S., Hendry J.H. Clonogenic cells and stem cells in epidermis. – Intern. J. Radiat. Biol, 1973, v. 24, No. 5, p. 537.

Potten C.S. Schofield R, Lajtha L.G. A comparison of cell replacement in bone marrow, testis and three regions of surface epithelium. – Biochem. Biophys. Acta, 1979, v. 560, No. 2, p. 281.

Rheinwald J.G. Green H. Epidermal growth factor and the multiplication of cultured human epidermal keratinocytes. – Nature, 1977, v. 265, No. 5593, p. 421.

Smith J.A., Martin L. Do cell cycle? – Proc Natl. Acad. Sci. USA, 1973, v. 70, No. 4, p. 1236.

 

Институт химической физики АН СССР

Москва

 

Поступила в редакцию

3.XI.1981

 

Khyalyavkin A.V.

The local heterogeneity of the basal cells of epidermis

 

Institute of Chemical Physics, Academy of Sciences of the USSR, Moscow

 

The critical analysis of the concept, postulating the subdivision of the basal cells of the epidermis into the stem cells and the cells at the beginning of the differentiation is given. It was shown that the experimental data, providing the basis of the concept, can be interpreted within the limits of the classical scheme of keratinocyte’s histogenesis, according to which all basal cells are know as stem cells, but their heterogeneity in a number of properties can be related with the different place in the cellular cycle. The experiment, the results of which can be used as the argument in favor of one of the alternative concepts, is suggested.

 

 

Локалная гетерогенность базальных клеток эпидермиса.

Khalyavkin Local Heterogeneity of Basal Epidermis Cells 82 5

 

—–

Epidermal homeostasis and the problem of psoriasis

 

Izvestia Akademii Nauk SSSR. Seria Biologicheskaya. 1, 156-159, 1982.

 

(Bulletin of the USSR Academy of Sciences. Biology Series. Vol. 1, pp. 156-159, 1982)

 

Alexander Khalyavkin

In Russian: Эпидермальный Гомеостаз и Проблема Псориаза

Khalyavkin Epidermal Homeostasis 82 1

 

 

Abstract

We consider a qualitative model of epidermal homeostasis, based on literature data. It is assumed that heterogeneous mitotic activity of the basal layer is responsible for the wave-like form of the dermo-epidermal boundary and is related to the specifics of the position of sub-epidermal lymphatic capillaries. We consider the conditions under which an increase of mitotic activity leads to an abnormally high transition of cells to differentiation, but only in some zones of the basal layer. We show that such an imbalance of cell streams can lead to the main histological signs of psoriasis, namely acanthosis, papillomatosis and parakeratosis.

 

Psoriasis is a widespread chronic disease of the skin with uncertain etiology and pathogenesis (Mordovzev, 1977; Skripkin, 1980; Flaxman et al. 1979 and others). The main signs of the disease are increased squamous appearance of the surface layers of the epidermis and their immaturity (parakeratosis), the anomalously high mitotic activity of the keratinocytes, the elongation of epidermal outgrowths accompanied by in-growth into the epidermis of dermal papillae along with thinning of the above-papillae areas of the epidermis (acanthosis and papillomatosis) and some others. The existing methods of therapy do to produce a lasting effect. The absence of an analogous disease in animals is a serious drawback for the experimental study of this pathology. The matter is further complicated by the fact that the epidermal homeostasis itself, whose impairment is assumed in psoriasis, has not been studied sufficiently (Mikhailv 1979, Skerrow1978). Therefore the current work makes an attempt to consider, based on the exiting data and concepts, a qualitative model of epidermal homeostasis and its impairment, possibly leading to psoriasis.

 

The surface of normal epidermis is the cornea, the end product of the skin epithelium differentiation. During the life course, the cells of the upper layers of the cornea are gradually shed and gradually replaced by mature cells from lower differentiating layers. These, in turn, are replaced by cells of the basal layer making a transition toward differentiation. The replenishment of the population of basal stem cells takes place thanks to their proliferation.

 

The profile of the epidermis at the border with the dermis is a wave-like line. The degree of undulation in different parts of the skin varies greatly, in correlation with the thickness of the epidermis and mitotic activity (Bullough, Deol, 1975). The proliferative activity of the basal layer is maximal at the basis of epidermal outgrowths. At a greater distance from these zones, the activity gradually decreases, reaching the minimal values at the basal cells, found above the dermal papillae (Flaxman, 1972; Fukuda et al. 1978). The reason for this is unknown. Possibly, the proliferative zones concentrate clonogenic cells, whose existence was hypothesized by Potten (Potten, Hendry, 1973), or non-committed stem cells insensitive to the action of G1-Chalone, posited by Marks (Marks 1976). It was also suggested that the localization of proliferative and non-proliferative zones is related to the specific location of blood vessels in the underlying derma (Fukuda et al. 1978). However, apparently, the heterogeneous mitotic activity of the basal layer is not related to the underlying blood vascular net. This follows from the fact that the sub-epidermal plexus of blood capillaries repeats the contours of the dermo-epidermal boundary. In contrast to blood capillaries, the blind outgrowths of lymphatic capillaries reach only to the basis of epidermal outgrowths (Nadezhdin, 1951). Therefore the humoral factors, found in the lymphatic vessels, unlike mitogens carried by the blood stream, can stimulate the proliferation of basal cells located mainly in the immediate proximity of the expanded ends of lymphatic capillaries. Perhaps this is what causes the heterogeneous mitotic activity of the basal layer. The presumed mitogens circulating in the lymphatic system may be the hypothetical “mesenchymal factor” (Bullough, Deol, 1975) or normal anti-tissue antibodies which are dedicated to tissue-specific stimulation of proliferation, according to several authors (Piatnizky, Makhlin, 1969, Babaeva, 1972; Khalyavkin 1975; Burwell, 1963). Healthy persons show the presence of normal anti-epidermal auto-antibodies, while psoriasis patients show their increased amounts (Beutner et al. 1977; Krogh, 1977). Even though in these and other studies, the main focus is on auto-antibodies to the surface layer of the epidermis, Krogh does not exclude the possibility that increased amounts of auto-antibodies to the growth layer can be the cause of its enhanced proliferation as observed in psoriasis (Krogh, 1977). It should be noted that for the first time such a concept was expressed in a theoretical work dedicated to the problem of psoriasis, already in 1965 (Burch, Rowell, 1965). In any case, whatever the actual cause for the heterogeneous mitotic activity of the basal cells, found in different locations of the dermo-epidermal boundary, it can also be the cause for the wave-like appearance of this boundary. Indeed, normally the speed of migration for cells transiting to differentiation from various locations of the basal layer should be balanced in such a way that such cells should reach the skin surface simultaneously. The mechanism of cell migration into the upper layers of the epidermis is little known (Skerrow, 1978). It may be assumed that the probability of transition to differentiation and therefore the starting speed of migration depend on dermo-epidermal adhesion and local inter-cellular pressure, created by mitotic activity (Iversen et al. 1968; Bullough, Deol, 1975). It is assumed that the dermo-epidermal adhesion is maximal for the basal cells found in the mitotic cycle, and minimal for the cells found in late G1 phase (apparently in G0 phase), therefore it is those cells that are most easily pushed toward differentiation (Iversen et al, 1968; Bullough, Deol, 1975). Therefore, for basal cells found in G0 phase, the probability to transit to differentiation and the starting speed of migration is the highest in places of maximal mitotic activity. When distancing from such places, the initial speeds of migration should decrease. Possibly, this is why the profile of the dermo-epidermal boundary is so convoluted that cells migrating upward with different average speed pass different distances, so that during the differentiation time Td they should reach about the same plane, which is the lower boundary of the cornea layer. An increase of average mitotic activity should and normally does lead to a more or less proportional increase of the maximal and minimal speeds of migration, and therefore to the thickening of the epidermis and greater convolution of the dermo-epidermal boundary. A significant increase in the average mitotic activity can result in a situation when the force of inter-cellular pressure, acting on the basal cells located at the basis of epidermal outgrowths, will exceed the maximal force of adhesion of cells with the underlying derma. Then the basal cells, found in the mitotic cycle and located in places of maximal inter-cellular pressure, under its effect will be either completely expelled toward differentiation, or more likely will change their orientation. The change of orientation can lead to the transformation of “horizontal” symmetrical mitoses into asymmetrical “vertical” ones, whose percentage increase under increased proliferation has been noted in the literature (Pinkus, Hunger, 1966; Duffill et al. 1977; Bullough, Mitrani, 1978). The proportional increase of the maximal and minimal speeds of migration implies a coordination of the action of two sub-epidermal humoral systems – the lymphatic and the blood systems. If there is no such coordination for some reason, there may emerge a situation when rapid increase of mitotic activity of basal cells located at the basis of epidermal outgrowths will not be accompanied by a proportional increase of this activity in basal cells located above the dermal papillae. This will lead to a disproportional elongation of epidermal outgrowths (acanthosis and papillomatosis). Such an elongation of outgrowths also means the increase of its basal cells. Since in this case this increase cannot take place at the expense of replication of cells found in the zones of maximal proliferation, where mitoses are asymmetrical, then it proceeds at the expense of cells in other zones. This should lead to a decline of transition to differentiation from these zones, and therefore to a shortening of the thickness of epidermis above the dermal papillae, exacerbating papillomatosis. Acanthosis and papillomatosis are the main histological signs of psoriasis alongside with parakeratosis or the immaturity of the surface layer. It is possible that parakeratosis is also the result of imbalance of cellular streams – a drastic increase of the maximal migration without a proportional increase of the minimal speed. Indeed, despite the significant elongation of epidermal outgrowths, the speed of migration is so large that the lower boundary of the cornea layer, formed above dermal papillae (Flaxman 1972), is reached by cells that transited to differentiation from the bottom of the epidermal outgrowth at a time significantly smaller than Td. During that time, judging form morphological and biochemical data, they do not mature even to the stage of granular cells. The increased amount of auto-antibodies to the surface layer of the epidermis, observed in psoriasis, according to some authors (Beutner et al. 1977; Krogh, 1977) facilitates the stratification of this immature layer, which normally has quite strong inter-cellular adhesion (Skerrow, 1978).

 

In the early stages of ontogenesis, when the biosynthesis of antibodies is still low, and the blind outgrowths of the lymphatic capillaries are not pronounced (Nadezhdin, 1951), the leading role in the control of proliferation may be played by humoral factors carried by the blood stream and equally available for all basal cells. Therefore the mitoses are distributed quite homogeneously, which can explain the smooth profile of epidermis in the new born and the low incidence of psoriasis at this age.

 

Thus, the present literature analysis allows us to conclude that the lack of coordination of sub-epidermal humoral systems accompanied by increased mitotic activity of keratinocytes can lead to an impairment of epidermal homeostasis and the emergence of the main signs of psoriasis.

 

References

 

Бабаева А. Г. Иммунологические механизмы регуляции восстановительных процессов. М. Медицина. 1972. 158 с. Babaeva A.G. Immunological mechanisms of regulation of repair processes. Moscow. Medicine, 1972 (in Russian)

 

Михайлов И. Н. Структура и функция эпидермиса. М. Медицина. 1979. 239 с. Mikhailov I.N. Structure and function of epidermis. Moscow. Medicine. 1979 (in Russian)

 

Мордовцев В. Н. Роль наследственных факторов при псориазе. Автореферат диссертации на соискание ученой степени доктора медицинских наук.. Москва. Центральный научно-исследовательский Кожно-венерологически институт. 1977. 35 с. Mordovzev V. N. The role of hereditary factors in psoriasis. PhD dissertation. Moscow. 1977 (in Russian).

 

Надеждин. В.Н. Архитектура начальных лимфатических сетей кожи нижней конечности человека. В кн – Анатомия лимфатической системы кожи человека. Л. Гос. Изд-во Мед. Лит. 1951. с. 115. Nadezhdin V.N. Architecture of the initial lymphatic nets of skin of human lower extremities. In: Anatomy of the lymphatic system of human skin. Leningrad. 1951.

 

Пятницкий Н.Н., Махлин Н.В. Нормальнее антитела, физиологическая регенерация и трансплантация органов. В кн. Актуальные проблемы пересадки органов. М. Медицина. 1969. с. 41. Piatnizky N.N. Machlin N.V. Normal antibodies, physiological regeneration and transplantaiton of organs. In: Current problems of organ transplantation. Moscow. 1969.

 

Скрипкин Ю.К. Кожные и венерологические болезни. М. Медицина. 1980. 550 с. Skripkin Y. K. Skin and venereal diseases. Moscow. 1980.

 

Халявкин А.В. Цензорно-ростовая модель и иммунитет. Изв. АН ГССР. Сер биол. 1975. т. 1. н. 5. с 490. Khalyavkin A.V. The censorial-growth model and immunity. 1975.

 

Beutner E. H. Chorzelski T.P., Jablonska S. Autoimmunity in psoriasis. Studies on the possible significance of the universal stratum corneum antibodies in the pathogenesis of psoriasis. In: Psoriasis. N.Y. Yorke Medical books, 1977, p. 63.

 

Bullough W.S., Deol J.U.R. Dermo-epidermal adhesion and its effect on epidermal structure in mouse. Brit Dermatol. 1975, v. 93, No. 4, p. 417.

 

Bullough W.S., Mitrani E. The significance of vertical mitosis in epidermis. Brit J. Dermatol. , 1978, v. 99, no. 6, p. 603.

 

Burch P.R.J., Rowell N.R. Psoriasis: aetiological aspects. Acta Derm-venereol. 1965, v. 45, No. 5, p. 366.

 

Burwell R. S. The role of lymphoid tissue in morphostasis. Lancet, 1963. v. 2, No. 7297, p. 69.

 

Duffill M.B., Appleton D.R., Dyson P., Shuster S., Wright N.A. The measurement of the cell cycle time in squamous epithelium using the metaphase arrest technique with vincristine. Brit. J. Dermatol. 1977, v. 96, p. 493.

 

Flaxman B.A. Replication and differentiation in vitro of epidermal cells from normal skin and from benign (psoriasis) and malignant (basal cell caner) hyperplasia. In vitro, 1972, b. 8, No. 3, p. 327.

 

Flaxman B.A., Karasek M., Voorhess J.J. Research needs in 11 major areas in dermatology. 1. Psoriasis. J. Invest. Dermatol. 1979, v. 73, No. 5, part 2, p. 402.

 

Fukuda M. Okamura K, Fujita S., Bohm M, Rohrbach R., Sadritter W. The different stem cell populations in mouse epidermis and lingual epithelium. Path Res. Pract. 1979. v. 1963, No. 3, p. 205.

 

Iversen O.H., Bjerknes R., Devik F. Kinetics of cell renewal, cell migration and cell loss in the hairless mouse dorsal epidermis. Cell Tissue Kinet. 1968, v. 1 No. 4, p. 351.

 

Krogh H. The significance of stratum corneum antibodies: an experimental model in guinea pigs. In: Psoriasis. N.Y. Yorke Medical Books. 1977. p. 55.

 

Marks F. Epidermal growth control mechanisms, hyperplasia, and tumor promotion in the skin. Cancer Res. 1976, v. 36, no. 7, part 2, p. 2636.

 

Pinkus H., Hunter R. The direction of the mitotic axis in human epidermis. Arch Dermatol 1966. v. 94, no. 4, p. 351.

 

Potten C.S., Hendry J.H., Clonogenic cells and stem cells in epidermis. Int J. Radiat. Biol. 1973, v. 24, No. 5, p. 537.

 

Skerrow C. J. Intercellualr adhesion and its role in epidermal differentiation. Invest. Cell Pathol. 1978, v. 1, No. 1, p. 23.

 

 

Institute of Chemical Physics. USSR Academy of Sciences. Msocw.

 

Arrived at the Editorial Office. 10. II. 1981.

 

Original abstract:

 

Khalyavkin A.V. The Epidermal homeostasis and the problem of psoriasis

 

Institute of Chemical Physics, Academy of Sciences of the USSR, Moscow

 

It was stated that the irregular mitotic activity of the basal layer is responsible for the wavy character of the dermo-epidermal borderline and related by the specificity of the subepidermal lymphatic capillaries’ distribution. On the basis of the literature data’s analysis the conclusion is made that the non-co-ordination of the action of the subepidermal human systems, aimed at the increase of the mitotic activity of the keratinocytes can lead to the disturbances in the epidermal homeostasis and appearance of acanthosis, papillomatosis and parakeratosis in the psoriasis development.

In Russian: Эпидермальный Гомеостаз и Проблема Псориаза

Khalyavkin Epidermail Homeostasis 82 1

Censor-Growth Model and Immunity

Censor-Growth Model and Immunity ORIGINAL 1975

Halyavkin-Censor Growth Model and Immunity-Thymus

ИЗВЕСТИЯ   АКАДЕМИИ   НАУК   ГССР Серия биологическая, т. 1, № 5, 6, 1975

КРАТКИЕ СООБЩЕНИЯ

 

УДК 577.95

ТЕОРЕТИЧЕСКАЯ БИОЛОГИЯ

 

ЦЕНЗОРНО-РОСТОВАЯ МОДЕЛЬ И ИММУНИТЕТ* А. В. Халявкин

Институт физиологии АН ГССР, Тбилиси Поступила в редакцию 10.10.1975

 

CENSOR-GROWTH MODEL AND IMMUNITY

  1. V. HALYAVKIN

Institute of Physiology, Georgian Academy of Sciences, Tbilisi. USSR Summary

A model is offered according to which the immunological phenomena are соnsidered not as the obligatory defense mechanisms, but as a particular case of the mechanism of specific stimulation of mitosis.

In Russian: Ц Е Н З О Р Н О – Р О С Т О В А Я М О Д Е Л Ь И И М М У Н И Т Е Т

Censor-Growth Model and Immunity

Censor-Growth Model and Immunity ORIGINAL 1975

Halyavkin-Censor Growth Model and Immunity-Thymus

 

 

 

 

Degenerative Aging as a Treatable Condition

whologoRecognizing Degenerative Aging as a Treatable Medical Condition

 

Ilia Stambler, PhD

 

There has been recently an intensifying discussion among longevity researchers and advocates about the inclusion of the Degenerative Aging Process as a recognized and treatable medical condition, that would include the systemic factors that contribute to diseases and frailty.

http://journal.frontiersin.org/article/10.3389/fgene.2015.00205/full

http://journal.frontiersin.org/article/10.3389/fgene.2015.00202/full

The underlying, apparently plausible rationale for this suggestion is that the recognition of degenerative aging as a treatable medical condition would enable the existing legal frameworks to better tackle diseases and conditions that arise from the aging process from a preventative healthcare model. In particular, pharmaceutical, biomedical and wellness industry could then develop for market quickly new and existing preventative medications, biomedical technologies and regimens, that would decrease long-term healthcare costs. Moreover, such a recognition would open up new public funding for new pharmaceutical and biomedical research and development. However, how do we achieve this recognition within the existing legal frameworks? And, more importantly, how do we translate this formal recognition into implementation, into establishing new research, development and healthcare programs at the international, national and institutional levels? And even more importantly, how do we translate these programs into actual biomedical treatments and cures, effective, safe and accessible for the widest public possible?

All these issues must become a subject of massive and pluralistic consultation of scientists and other stakeholders. An initial deliverable could be a collection of papers and expert opinions dedicated to the subject. With this evidential and expert basis, it may be expedient to develop more precise policy recommendations and approaches for further consultation with the relevant WHO departments and affiliates, such as the Global Burden of Disease (GBD) program, the WHO Multi-Country Studies Unit, the WHO Collaborating Centre on International Longitudinal Studies of Gender, Ageing and Health, the developers of the ICD and ISF, WHO Department of Aging and Lifecourse, in particular the GSAP, WHO Program on Non-communicable Diseases and their Risk Factors, UN NGO Committee on Aging, UN Department of Economic and Social Affairs – Division for Social Policy and Development, implementation agencies of the UN Sustained Development Goals (esp. SDG3 on healthcare)  and other relevant authorities.

http://www.who.int/entity/en/